# Northern District of California

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

# UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA

PLEXXIKON INC.,

Plaintiff,

v.

NOVARTIS PHARMACEUTICALS CORPORATION,

Defendant.

Case No. 17-cv-04405-HSG

# ORDER GRANTING IN PART AND **DENYING IN PART MOTIONS TO SEAL**

Re: Dkt. Nos. 149, 164, 166, 168, 176, 178, 185, 187, 193, 196, 199, 201, 203, 205, 207, 209, 211, 224, 226, 231, 232, 235, 242, 258, 261, 263, 265, 267, 282, 285, 287, 289, 291, 293, 295, 297, 299, 306, 314, 332, 363, 366, 368, 374

Pending before the Court are the parties' administrative motions to file under seal portions of documents in connection with motions for partial summary judgment, *Daubert* motions, and motions in limine filed by Plaintiff Plexxikon Inc. and Defendant Novartis Pharmaceuticals Corporation (twenty-eight total). For the reasons detailed below, the Court **GRANTS IN PART** and **DENIES IN PART** the motions to file under seal.

## I. LEGAL STANDARD

Courts generally apply a "compelling reasons" standard when considering motions to seal documents. Pintos v. Pac. Creditors Ass'n, 605 F.3d 665, 678 (9th Cir. 2010) (quoting Kamakana v. City & Cty. of Honolulu, 447 F.3d 1172, 1178 (9th Cir. 2006)). "This standard derives from the common law right 'to inspect and copy public records and documents, including judicial records and documents." Id. (quoting Kamakana, 447 F.3d at 1178). "[A] strong presumption in favor of access is the starting point." Kamakana, 447 F.3d at 1178 (quotations omitted). To overcome this strong presumption, the party seeking to seal a judicial record attached to a dispositive motion must "articulate compelling reasons supported by specific factual findings that outweigh the general history of access and the public policies favoring disclosure, such as the public interest in

understanding the judicial process" and "significant public events." *Id.* at 1178–79 (quotations omitted). "In general, 'compelling reasons' sufficient to outweigh the public's interest in disclosure and justify sealing court records exist when such 'court files might have become a vehicle for improper purposes,' such as the use of records to gratify private spite, promote public scandal, circulate libelous statements, or release trade secrets." *Id.* at 1179 (quoting *Nixon v. Warner Commc'ns, Inc.*, 435 U.S. 589, 598 (1978)). "The mere fact that the production of records may lead to a litigant's embarrassment, incrimination, or exposure to further litigation will not, without more, compel the court to seal its records." *Id.* 

Civil Local Rule 79-5 supplements the "compelling reasons" standard. The party seeking to file under seal must submit "a request that establishes that the document, or portions thereof, are privileged, protectable as a trade secret or otherwise entitled to protection under the law . . . . The request must be narrowly tailored to seek sealing only of sealable material . . . ." Civil L.R. 79-5(b). Courts have found that "confidential business information" in the form of "license agreements, financial terms, details of confidential licensing negotiations, and business strategies" satisfies the "compelling reasons" standard. *See In re Qualcomm Litig.*, No. 3:17-cv-0108-GPC-MDD, 2017 WL 5176922, at \*2 (S.D. Cal. Nov. 8, 2017) (observing that sealing such information "prevent[ed] competitors from gaining insight into the parties' business model and strategy"); *Finisar Corp. v. Nistica, Inc.*, No. 13-cv-03345-BLF (JSC), 2015 WL 3988132, at \*5 (N.D. Cal. June 30, 2015).

Records attached to nondispositive motions must meet the lower "good cause" standard of Rule 26(c) of the Federal Rules of Civil Procedure, as such records "are often unrelated, or only tangentially related, to the underlying cause of action." *Id.* at 1179–80 (quotations omitted). This requires a "particularized showing" that "specific prejudice or harm will result" if the information is disclosed. *Phillips ex rel. Estates of Byrd v. Gen. Motors Corp.*, 307 F.3d 1206, 1210–11 (9th Cir. 2002); *see also* Fed. R. Civ. P. 26(c). "Broad allegations of harm, unsubstantiated by specific examples of articulated reasoning" will not suffice. *Beckman Indus., Inc. v. Int'l Ins. Co.*, 966 F.2d 470, 476 (9th Cir. 1992) (quotation omitted).

//

# II. DISCUSSION

Because the parties seek to seal portions and documents which pertain to summary judgment motions, the Court applies the compelling reasons standard to these documents. The Court applies the lower good cause standard for those documents related to the parties' *Daubert* motions and motions in limine.

As indicated in the table below, the only proffered justification for sealing many of the documents is that the information was designated as "highly confidential" by either Plaintiff, Defendant, or non-parties GlaskoSmithKline PLC and GlaskoSmithKline LLC. But a designation of confidentiality is not sufficient to establish that a document is sealable. *See* Civ. L. R. 79-5(d)(1)(A). "Confidential" is merely the parties' initial designation of confidentiality to establish coverage under the stipulated protective order. *See Verinata Health, Inc. v. Ariosa Diagnostics, Inc.*, No. 12-cv-05501-SI, 2015 WL 5117083, at \*5 (N.D. Cal. Aug. 31, 2015) ("But good cause 'cannot be established simply by showing that the document is subject to a protective order or by stating in general terms that the material is considered to be confidential") (quoting *Bain v. AstraZeneca LP*, No. 09-cv-4147, 2011 WL 482767, at \*1 (N.D. Cal. Feb. 7, 2011)). Thus, many of the parties' motions do not comply with Civil Local Rule 79-5(d)(1)(A). In addition, in many instances the designating party for the materials did not comply with Civil Local Rule 79-5(e)(1), because they did not file a declaration within four days of the motion. *See* Civ. L.R. 79-5(e)(1). The Court finds that sealing is not warranted as to those documents.

Nevertheless, the Court finds that as to the remaining motions to seal, the parties have narrowly tailored their requested redactions to confidential and proprietary business, scientific, manufacturing, sales, or licensing information. The public release of these documents could give non-party competitors an unfair advantage in the development or marketing of rival products. *See In re Elec. Arts, Inc.*, 298 F. App'x 568, 569 (9th Cir. 2008) (ordering sealing where documents could be used "as sources of business information that might harm a litigant's competitive standing") (quoting *Nixon v. Warner Commc'ns, Inc.*, 435 U.S. 589, 598 (1978)). Thus, the Court finds that the parties have in those circumstances established either compelling reasons or good cause to grant the motions to file under seal. *See, e.g., Linex Techs., Inc. v. Hewlett-Packard* 

Co., No. C 13-159 CW, 2014 WL 6901744 (N.D. Cal. Dec. 8, 2014); Apple Inc. v. Samsung Elecs. Co., Ltd., No. 11-CV-01846-LHK, 2012 WL 6115623 (N.D. Cal. Dec. 10, 2012).

Docket No.	Document	Portion(s) Sought to be	Ruling
Public /(Sealed)		Sealed	
		9 – GRANTED	
Dkt. No. 150-1/ (149-4)	Exhibit A to the Declaration of Daralyn J. Durie in Support of March 18, 2019 Discovery Letter	Entire document	GRANTED (Contains proprietary pharmaceutical research and development information. <i>See</i> Dkt No. 153.)
	Dkt. No. 1	164 – DENIED	
Dkt. No. 165/ (164-4)	Plaintiff's Notice of Motion and Motion to Exclude Certain Opinions and Testimony of Novartis's Technical Experts	Page 2:15–28 Page 3:1–13, 18–20 Page 4:4–15, 19–20 Page 5:5–12, 18–20, 24– 26 Page 6:13–15 Page 8:19–24 Page 9:1–5 Page 10:1–6, 15–22, 27– 28 Page 11:25–28 Page 12:1–2, 9–11	<b>DENIED</b> (No supporting declaration filed. <i>See</i> Civ. L.R. 79-5(e)(1).)
Dkt. No. 165-2/ (164-6)	Exhibit 1 to the Declaration of Laura E. Miller in Support of Plaintiff's Motion to Exclude the Opinions and Testimony of Novartis's Technical Experts	Entire document	<b>DENIED</b> (No supporting declaration filed. <i>See</i> Civ. L.R. 79-5(e)(1).)
Dkt. No. 165-3/ (164-8)	Exhibit 2 to the Declaration of Laura E. Miller in Support of Plaintiff's Motion to Exclude the Opinions and Testimony of Novartis's Technical Experts	Entire document	<b>DENIED</b> (No supporting declaration filed. <i>See</i> Civ. L.R. 79-5(e)(1).)
Dkt. No. 165-5/ (164-10)	Exhibit 4 to the Declaration of Laura E. Miller in Support of Plaintiff's Motion to Exclude the Opinions and Testimony of Novartis's	Entire document	<b>DENIED</b> (No supporting declaration filed. <i>See</i> Civ. L.R. 79-5(e)(1).)

strict Court	of California
United States District (	Northern District of

	Technical Experts		
Dkt. No. 165-6/	Exhibit 5 to the	Entire document	DENIED
(164-12)	Declaration of Laura E.		(No supporting
	Miller in Support of		declaration filed. Se
	Plaintiff's Motion to		Civ. L.R. 79-5(e)(1)
	Exclude the Opinions and		
	Testimony of Novartis's		
	Technical Experts		
Dkt. No. 165-8/	Exhibit 7 to the	Entire document	DENIED
(164-14)	Declaration of Laura E.		(No supporting
,	Miller in Support of		declaration filed. Se
	Plaintiff's Motion to		Civ. L.R. 79-5(e)(1)
	Exclude the Opinions and		
	Testimony of Novartis's		
	Technical Experts		
	Okt. No. 166 – GRANTED I	N PART and DENIED IN	PART
Dkt. No. 167/	Plaintiff's Notice of	Page 1:8–9, 13–18	DENIED
(166-4)	Motion and Motion for	Page 2:9	(No supporting
	Summary Judgment of No	Page 5:17–22, 26–28	declaration filed. Se
	Anticipation	Page 6:1–10	Civ. L.R. 79-5(e)(1)
	_	Page 11:13–22	
		Page 12:3, 6–18, 20	
		Page 13:17–18, 20–24	
		Page 14:1–2	
		Page 15:13–14, 21–24	
		Page 16:1–7, 10, 12	
		Page 17:13–14	
Dkt. No. 167-2/	Exhibit 1 to the	Entire document	DENIED
(166-6)	Declaration of Matthew		(No supporting
	W. Samuels in Support of		declaration filed. Se
	Plaintiff's Motion for		Civ. L.R. 79-5(e)(1)
	Summary Judgment of No		
	Anticipation		
Dkt. No. 167-10/	Exhibit 9 to the	Entire document	DENIED
(166-8)	Declaration of Matthew		(No supporting
	W. Samuels in Support of		declaration filed. Se
	Plaintiff's Motion for		Civ. L.R. 79-5(e)(1)
	Summary Judgment of No		
	Anticipation		
Dkt. No. 167-20/	Exhibit 19 to the	Entire document	DENIED
(166-10)	Declaration of Matthew		(No supporting
,	W. Samuels in Support of		declaration filed. Se
	Plaintiff's Motion for		Civ. L.R. 79-5(e)(1)
	Summary Judgment of No		- (-)(-)
	Anticipation		
Dkt. No. 167-21/	Exhibit 20 to the	Entire document	GRANTED
			(Contains proprietar
(166-12)	Declaration of Matthew		(Contains broblietai

	Plaintiff's Motion for Summary Judgment of No Anticipation		research and development information. <i>See</i> Dkt. No. 171.)
Dkt. No. 167-22/ (166-14)	Exhibit 21 to the Declaration of Matthew W. Samuels in Support of Plaintiff's Motion for Summary Judgment of No Anticipation	Entire document	GRANTED (Contains proprietary pharmaceutical research and development information. <i>See</i> Dkt. No. 171.)
	Dkt. No. 1	168 – DENIED	
Dkt. No. 169/ (168-10)	Plaintiff's Notice of Motion and Motion to Exclude the Opinions and Testimony of James E. Malackowski	Page i:7–10 Page 1:6–9, 12–15, 20 Page 2:7–10, 16–28 Page 3:1–28 Page 4:1–6 Page 7:3–28 Page 8:1–2, 4–15, 19–20, 26–27 Page 9:8–17 Page 10:1–7, 16–28 Page 11:1, 11–12, 14–24 Page 12:4–5, 16–28 Page 13:1–14, 17–28 Page 14:1–17, 19–20	(No supporting declaration filed. <i>See</i> Civ. L.R. 79-5(e)(1).)
Dkt. No. 169-1/ (168-4)	Exhibit 1 to the Declaration of Laura E. Miller in Support of Plaintiff's Motion to Exclude the Opinions and Testimony of James E. Malackowski	Entire document	<b>DENIED</b> (No supporting declaration filed. <i>See</i> Civ. L.R. 79-5(e)(1).)
Dkt. No. 169-3/ (168-8)	Exhibit 2 to the Declaration of Laura E. Miller in Support of Plaintiff's Motion to Exclude the Opinions and Testimony of James E. Malackowski	Entire document	<b>DENIED</b> (No supporting declaration filed. <i>See</i> Civ. L.R. 79-5(e)(1).)
Dkt. No. 169-4/ (168-8)	Exhibit 3 to the Declaration of Laura E. Miller in Support of Plaintiff's Motion to Exclude the Opinions and Testimony of James E. Malackowski	Entire document	<b>DENIED</b> (No supporting declaration filed. <i>See</i> Civ. L.R. 79-5(e)(1).)

	Okt. No. 176 – GRANTED I		_
Dkt. No. 177/ (176-4)	Defendant's Notice of Motion and Motion for Partial Summary Judgment	Page 2:16, 24–28 Page 3:6–14, 21–26 Page 4:1–2, 7–11 Page 5:11–26 Page 6:1–13 Page 7:2–18, 20 Page 8:8–12, 26–27 Page 9:1–2, 6–15 Page 12:28 Page 13:1, 5–8, 10–18 Page 14:5–9 Page 15:25–27 Page 16:21–22 Page 17:15–18	GRANTED IN PART (The following contains proprietary pharmaceutical research and development information:  Page 3:6–14, 21–26 Page 4:1–2, 7–11 Page 5:11–26 Page 6:1–13 Page 12:28 Page 13:1, 5–8 10–18 Page 14:5–9
Dkt. No. 177-16/ (176-12)	Declaration of Tara R. Rheault, PhD., In Support of Defendant's Motion for Partial Summary Judgment	Page 2:3, 7, 10, 23, 25–26 Page 3:1–27 Page 4:1, 3–12	See Dkt. No. 182.)  GRANTED  (Contains proprietar pharmaceutical research and development information. See Dl No. 182.)
Dkt. No. 177-17/ (176-13)	Exhibit 1 to the Declaration of Tara R. Rheault, PhD., In Support of Defendant's Motion for Partial Summary Judgment	Entire document	GRANTED (Contains proprietar pharmaceutical research and development information. See Di No. 182.)
Dkt. No. 177-18/ (176-14)	Exhibit 2 to the Declaration of Tara R. Rheault, PhD., In Support of Defendant's Motion for Partial Summary Judgment	Entire document	GRANTED (Contains proprietar pharmaceutical research and development information. See Di No. 182.)
Dkt. No. 177-2/ (176-6)	Declaration of Phil S. Baran, PhD., In Support of Defendant's Motion for Partial Summary Judgment	Page 2:11–16, 18–27 Page 3:1, 11–18 Page 4:9–13 Page 5:5–23, 25–26 Appendix A, pp. 1–3, 9– 11, 19 Appendix B in its entirety	GRANTED (Contains proprietar pharmaceutical research and development information. See DI No. 182.)

# United States District Court Northern District of California

Dkt. No. 177-6/	Exhibit 4 to the	Entire document	GRANTED
(Native Excel	Declaration of		(Contains trade
File)	Phil S. Baran, PhD., In		secrets, as well as
	Support of Defendant's Motion for Partial		proprietary
			pharmaceutical research and
	Summary Judgment		development
			information. See Dkt.
			No. 182.)
Dkt. No. 177-7/	Exhibit 5 to the	Entire document	GRANTED
(176-7)	Declaration of	Entire document	(Contains trade
(1707)	Phil S. Baran, PhD., In		secrets, as well as
	Support of Defendant's		proprietary
	Motion for Partial		pharmaceutical
	Summary Judgment		research and
	2 dilling of diagnitude		development
			information. See Dkt.
			No. 182.)
Dkt. No. 177-8/	Exhibit 6 to the	Entire document	GRANTED
(176-8)	Declaration of		(Contains trade
,	Phil S. Baran, PhD., In		secrets, as well as
	Support of Defendant's		proprietary
	Motion for Partial		pharmaceutical
	Summary Judgment		research and
			development
			information. See Dkt.
			No. 182.)
Dkt. No. 177-9/	Exhibit 7 to the	Entire document	GRANTED
(176-9)	Declaration of		(Contains trade
	Phil S. Baran, PhD., In		secrets, as well as
	Support of Defendant's		proprietary
	Motion for Partial		pharmaceutical
	Summary Judgment		research and
			development
			information. See Dkt.
D1 37 455 444	F 131 12 12		No. 182.)
Dkt. No. 177-14/	Exhibit 12 to the	Entire document	DENIED
(176-10)	Declaration of		(No supporting
	Phil S. Baran, PhD., In		declaration filed. See
	Support of Defendant's		Civ. L.R. 79-5(e)(1).)
	Motion for Partial		
Dlst No. 177 207	Summary Judgment	Entino do assessor d	DENIED
Dkt. No. 177-20/	Exhibit 1 to the	Entire document	DENIED (No supporting
(176-15)	Declaration Of Thomas P. Staindler In		(No supporting
	Thomas P. Steindler In		declaration filed. See
	Support Of Defendant's Motion For Partial		Civ. L.R. 79-5(e)(1).)
	Summary Judgment		

	a
Court	forni
C T	alif
stric	District of Calif
Z.	ict
United States District (	)istı
d St	Н
nite	Vorthern
	9

[	I =	I	T =
Dkt. No. 177-22/	Exhibit 3 to the	Entire document	DENIED
(176-16)	Declaration Of		(No supporting
	Thomas P. Steindler In		declaration filed. See
	Support Of Defendant's		Civ. L.R. 79-5(e)(1).)
	Motion For Partial		
	Summary Judgment		
		178 – DENIED	T
Dkt. No. 179/	Defendant's Notice of	Page i:12	DENIED
(178-4)	Motion and Motion to	Page 2:2–3, 5–6, 8, 9, 12–	(No supporting
	Strike Portions	15, 18–19, 21	declaration filed. See
	of Expert Report of	Page 5:10–12, 16–23	Civ. L.R. 79-5(e)(1).)
	Plaintiff's Expert Michael	Page 6:8	
	L. Metzker, Ph.D.	Page 7:5, 7, 10, 15, 18–19,	
		20, 24	
		Page 8:3, 7, 11, 16, 20,	
		27–28	
		Page 9:1–2, 16	
Dkt. No. 179-3/	Exhibit 1 to the	Entire document	DENIED
(178-5)	Declaration of David		(No supporting
	Mlaver In Support Of		declaration filed. See
	Defendant's Motion To		Civ. L.R. 79-5(e)(1).)
	Strike Portions of Expert		
	Report of Plaintiff's		
	Expert Michael L.		
	Metzker, Ph.D.		
Dkt. No. 179-7/	Exhibit 5 to the	Pages 12–15	DENIED
(178-7)	Declaration of David		(No supporting
	Mlaver In Support Of		declaration filed. See
	Defendant's Motion To		Civ. L.R. 79-5(e)(1).)
	Strike Portions of Expert		
	Report of Plaintiff's		
	Expert Michael L.		
	Metzker, Ph.D.		
Dkt. No. 179-9/	Exhibit 7 to the	Entire document	DENIED
(178-8)	Declaration of David		(No supporting
	Mlaver In Support Of		declaration filed. See
	Defendant's Motion To		Civ. L.R. 79-5(e)(1).)
	Strike Portions of Expert		
	Report of Plaintiff's		
	Expert Michael L.		
	Metzker, Ph.D.		
]	Okt. No. 185 – GRANTED I	N PART and DENIED IN I	PART
Dkt. No. 186/	Defendant's Opposition	Page 4:8, 13	GRANTED IN
(185-4)	To Plaintiff's Motion For	Page 5:13	PART
,	Summary Judgment Of	Page 7:25	(The following
	Summary Judgment Of	1 450 7.25	\
	No Anticipation	Page 10:7	contains proprietary
		<u> </u>	

Court	alifornia
States District Co	strict of Calif
United Stat	Jorthern Dis

Dkt. No. 186-3/ (185-5)	Exhibit 2 to the Declaration of Thomas P. Steindler In Support Of Defendant's Opposition To Plaintiff's Motion For Summary Judgment Of No Anticipation	Page 16:12–13, 23–25 Page 17:15–16, 20–21 Page 18:15–18, 24–26 Page 19:8–9 Entire document	development information:  • Page 15:10–17  See Dkt. No. 190.)  DENIED  (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 186-4/ (185-7)	Exhibit 3 to the Declaration of Thomas P. Steindler In Support Of Defendant's Opposition To Plaintiff's Motion For Summary Judgment Of No Anticipation	¶¶ 80–84, 86–87, 99–108	GRANTED IN PART (The following contains proprietary pharmaceutical research and development information:  • ¶¶ 86, 104, 107, 108 See Dkt. No. 190.)
Dkt. No. 186-6/ (185-8)	Exhibit 5 to the Declaration of Thomas P. Steindler In Support Of Defendant's Opposition To Plaintiff's Motion For Summary Judgment Of No Anticipation	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 186-8/ (185-9)	Exhibit 7 to the Declaration of Thomas P. Steindler In Support Of Defendant's Opposition To Plaintiff's Motion For Summary Judgment Of No Anticipation	Entire document	DENIED (Defendant states, in conclusory fashion, that the documents "contain and refer to competitively sensitive documents the public disclosure of which would cause harm to Novartis."  See Dkt. No. 185-1. This generic explanation is insufficient to establish good cause.)
Dkt. No. 186-9/ (185-10)	Exhibit 8 to the Declaration of Thomas P. Steindler In Support Of	Entire document	GRANTED (Contains proprietary pharmaceutical

	Defendant's Opposition		research and
	To Plaintiff's Motion For		development
	Summary Judgment Of		information. See Dkt.
	No Anticipation		No. 190.)
Dkt. No. 186-10/	Exhibit 9 to the	Entire document	GRANTED
(185-11)	Declaration of Thomas P.		(Contains proprietary
	Steindler In Support Of		pharmaceutical
	Defendant's Opposition		research and
	To Plaintiff's Motion For		development
	Summary Judgment Of		information. See Dkt.
	No Anticipation		No. 190.)
Dkt. No. 186-11/	Exhibit 10 to the	Entire document	DENIED
(185-12)	Declaration of Thomas P.		(No supporting
,	Steindler In Support Of		declaration filed. See
	Defendant's Opposition		Civ. L.R. 79-5(e)(1).)
	To Plaintiff's Motion For		
	Summary Judgment Of		
	No Anticipation		
Dkt. No. 186-12/	Exhibit 11 to the	Entire document	DENIED
(185-13)	Declaration of Thomas P.		(No supporting
	Steindler In Support Of		declaration filed. See
	Defendant's Opposition		Civ. L.R. 79-5(e)(1).)
	To Plaintiff's Motion For		
	Summary Judgment Of		
	No Anticipation		
]	Okt. No. 187 – GRANTED I	N PART and DENIED IN I	PART
Dkt. No. 188/	Defendant's Opposition	Page i:8–10	DENIED
(187-4)	To Plaintiff's Motion To	Page 1:7–8, 10, 15–16, 21	(Defendant states, in
	Exclude The Opinions	Page 2:19–27	conclusory fashion,
	And Testimony Of James	Page 3:1–15, 18–19, 23,	that the documents
	E. Malackowski	25–26	"contain and refer to
	E. Malackowski	25–26 Page 5:3–5, 8, 13, 16, 19–	
	E. Malackowski		"contain and refer to
	E. Malackowski	Page 5:3–5, 8, 13, 16, 19–	"contain and refer to competitively
	E. Malackowski	Page 5:3–5, 8, 13, 16, 19–20, 23, 25–26	"contain and refer to competitively sensitive documents
	E. Malackowski	Page 5:3–5, 8, 13, 16, 19–20, 23, 25–26 Page 6:5	"contain and refer to competitively sensitive documents the public disclosure
	E. Malackowski	Page 5:3–5, 8, 13, 16, 19–20, 23, 25–26 Page 6:5 Page 7:12–14, 16–19, 23 Page 8:7, 13–17, 19, 20, 22, 24–28	"contain and refer to competitively sensitive documents the public disclosure of which would cause
	E. Malackowski	Page 5:3–5, 8, 13, 16, 19–20, 23, 25–26 Page 6:5 Page 7:12–14, 16–19, 23 Page 8:7, 13–17, 19, 20,	"contain and refer to competitively sensitive documents the public disclosure of which would cause harm to Novartis."
	E. Malackowski	Page 5:3–5, 8, 13, 16, 19–20, 23, 25–26 Page 6:5 Page 7:12–14, 16–19, 23 Page 8:7, 13–17, 19, 20, 22, 24–28	"contain and refer to competitively sensitive documents the public disclosure of which would cause harm to Novartis." See Dkt. No. 187-1.
	E. Malackowski	Page 5:3–5, 8, 13, 16, 19–20, 23, 25–26 Page 6:5 Page 7:12–14, 16–19, 23 Page 8:7, 13–17, 19, 20, 22, 24–28 Page 9:3, 6–7	"contain and refer to competitively sensitive documents the public disclosure of which would cause harm to Novartis."  See Dkt. No. 187-1. This generic
	E. Malackowski	Page 5:3–5, 8, 13, 16, 19–20, 23, 25–26 Page 6:5 Page 7:12–14, 16–19, 23 Page 8:7, 13–17, 19, 20, 22, 24–28 Page 9:3, 6–7 Page 10:5–7, 16–20, 25–28 Page 11:1–2, 27–28	"contain and refer to competitively sensitive documents the public disclosure of which would cause harm to Novartis."  See Dkt. No. 187-1.  This generic explanation is
Dkt. No. 188-2/	Exhibit A to the	Page 5:3–5, 8, 13, 16, 19–20, 23, 25–26 Page 6:5 Page 7:12–14, 16–19, 23 Page 8:7, 13–17, 19, 20, 22, 24–28 Page 9:3, 6–7 Page 10:5–7, 16–20, 25–28	"contain and refer to competitively sensitive documents the public disclosure of which would cause harm to Novartis."  See Dkt. No. 187-1.  This generic explanation is insufficient to establish good cause.)  GRANTED IN
Dkt. No. 188-2/ (187-5)	Exhibit A to the Declaration of Tom	Page 5:3–5, 8, 13, 16, 19–20, 23, 25–26 Page 6:5 Page 7:12–14, 16–19, 23 Page 8:7, 13–17, 19, 20, 22, 24–28 Page 9:3, 6–7 Page 10:5–7, 16–20, 25–28 Page 11:1–2, 27–28	"contain and refer to competitively sensitive documents the public disclosure of which would cause harm to Novartis."  See Dkt. No. 187-1.  This generic explanation is insufficient to establish good cause.)  GRANTED IN PART
	Exhibit A to the Declaration of Tom Steindler in Support of	Page 5:3–5, 8, 13, 16, 19–20, 23, 25–26 Page 6:5 Page 7:12–14, 16–19, 23 Page 8:7, 13–17, 19, 20, 22, 24–28 Page 9:3, 6–7 Page 10:5–7, 16–20, 25–28 Page 11:1–2, 27–28	"contain and refer to competitively sensitive documents the public disclosure of which would cause harm to Novartis."  See Dkt. No. 187-1.  This generic explanation is insufficient to establish good cause.)  GRANTED IN  PART  (Pages 12, 52–63
	Exhibit A to the Declaration of Tom Steindler in Support of Defendant's Opposition	Page 5:3–5, 8, 13, 16, 19–20, 23, 25–26 Page 6:5 Page 7:12–14, 16–19, 23 Page 8:7, 13–17, 19, 20, 22, 24–28 Page 9:3, 6–7 Page 10:5–7, 16–20, 25–28 Page 11:1–2, 27–28	"contain and refer to competitively sensitive documents the public disclosure of which would cause harm to Novartis."  See Dkt. No. 187-1.  This generic explanation is insufficient to establish good cause.)  GRANTED IN  PART  (Pages 12, 52–63 contain trade secrets
	Exhibit A to the Declaration of Tom Steindler in Support of Defendant's Opposition To Plaintiff's Motion To	Page 5:3–5, 8, 13, 16, 19–20, 23, 25–26 Page 6:5 Page 7:12–14, 16–19, 23 Page 8:7, 13–17, 19, 20, 22, 24–28 Page 9:3, 6–7 Page 10:5–7, 16–20, 25–28 Page 11:1–2, 27–28	"contain and refer to competitively sensitive documents the public disclosure of which would cause harm to Novartis."  See Dkt. No. 187-1.  This generic explanation is insufficient to establish good cause.)  GRANTED IN PART  (Pages 12, 52–63 contain trade secrets and highly
	Exhibit A to the Declaration of Tom Steindler in Support of Defendant's Opposition	Page 5:3–5, 8, 13, 16, 19–20, 23, 25–26 Page 6:5 Page 7:12–14, 16–19, 23 Page 8:7, 13–17, 19, 20, 22, 24–28 Page 9:3, 6–7 Page 10:5–7, 16–20, 25–28 Page 11:1–2, 27–28	"contain and refer to competitively sensitive documents the public disclosure of which would cause harm to Novartis."  See Dkt. No. 187-1.  This generic explanation is insufficient to establish good cause.)  GRANTED IN  PART  (Pages 12, 52–63 contain trade secrets

rict Court	California
nited States District Court	n District of Calif
United	Vorthern

	E. Malackowski		No. 191. As to the rest of the document, Defendant states, in conclusory fashion, that it "contain[s] and refer[s] to competitively sensitive" information. See Dkt. No. 187-1. This generic explanation is insufficient to establish good cause.)
Dkt. No. 188-3/ (187-6)	Exhibit B to the Declaration of Tom Steindler in Support of Defendant's Opposition To Plaintiff's Motion To Exclude The Opinions And Testimony Of James E. Malackowski	Entire document	<b>DENIED</b> (No supporting declaration filed. <i>See</i> Civ. L.R. 79-5(e)(1).)
Dkt. No. 188-4/ (187-7)	Exhibit C to the Declaration of Tom Steindler in Support of Defendant's Opposition To Plaintiff's Motion To Exclude The Opinions And Testimony Of James E. Malackowski	Entire document	DENIED (Defendant states, in conclusory fashion, that the documents "contain and refer to competitively sensitive documents the public disclosure of which would cause harm to Novartis."  See Dkt. No. 187-1. This generic explanation is insufficient to establish good cause.)
		193 – DENIED	/
Dkt. No. 194/ (193-4)	Plaintiff's Reply in Support of Its Motion to Exclude the Opinions and Testimony of James E. Malackowski	Page i:5–9 Page 1:5, 8–14, 17, 23–24 Page 2:9–11 Page 3:2, 27 Page 4:8–12, 21–25, 27–28 Page 5:1–2, 12–13, 15–16, 25–28 Page 6:1–2, 4–9, 14–17, 23–26 Page 8:3–13	<b>DENIED</b> (No supporting declaration filed. <i>See</i> Civ. L.R. 79-5(e)(1).)

		Page 9:9–10	
	Dkt. No. 1	196 – DENIED	
Dkt. No. 197/	Plaintiff's Reply in	Page 3:3–14	DENIED
(196-4)	Support of Its Motion to	Page 5:6–8, 24–28	(No supporting
	Exclude Certain Opinions	Page 6:1–18	declaration filed. See
	and Testimony of	Page 7:2–6	Civ. L.R. 79-5(e)(1).
	Novartis's Technical		
	Experts		
		199 – DENIED	
Dkt. No 200/	Defendant's Notice of	Page 2:14, 22–28	DENIED
(199-4)	Motion and Motion to	Page 3:1–12, 14–26	(No supporting
	Exclude Expert Testimony	Page 4:1–10	declaration filed. Se
	of Michael L. Metzker,	Page 5:23	Civ. L.R. 79-5(e)(1)
	Ph.D.	Page 6:7–8, 11–13, 17–	
		21, 24–25, 27–28	
		Page 7:5–6, 8–11, 14–28	
		Page 8:1–6, 16–17, 20–26	
		Page 9:3–6, 9, 10–13, 16–	
		19, 21, 22–24, 26–27	
		Page 10:1–11, 20–24	
		Page 11:6–8	
		Page 12:20, 24	
Dkt. No. 200-1/	Declaration of Phil S.	¶¶ 17–28, 30–35, 37–45,	DENIED
(199-6)	Baran, Ph.D. In Support	47, 49, 58, 59	(No supporting
,	Of Defendant's Motion to		declaration filed. Se
E	Exclude Expert Testimony		Civ. L.R. 79-5(e)(1)
	of Michael L. Metzker,		
	Ph.D.		
Dkt. No. 200-5/	Exhibit 3 to the	Entire document	DENIED
(199-7)	Declaration of Tom		(No supporting
` '	Steindler in Support of		declaration filed. Se
	Defendant's Motion to		Civ. L.R. 79-5(e)(1)
	Exclude Expert Testimony		
	of Michael L. Metzker,		
	Ph.D.		
Dkt. No. 200-6/	Exhibit 4 to the	Entire document	DENIED
(199-8)	Declaration of Tom		(No supporting
(177 6)	Steindler in Support of		declaration filed. Se
	Defendant's Motion to		Civ. L.R. 79-5(e)(1)
	Exclude Expert Testimony		
	of Michael L. Metzker,		
	Ph.D.		
Dkt. No. 200-7/	Exhibit 5 to the	Entire document	DENIED
(199-9) Del	Declaration of Tom		(No supporting
	Steindler in Support of		declaration filed. Se
	Defendant's Motion to		Civ. L.R. 79-5(e)(1)
	Exclude Expert Testimony		
	Laciade Lapert Leginiony	•	ì

Court	ifornia
United States District Court	District of Californi
States	n Distri
United	Vorthern

	Ph.D.		
Dkt. No. 200-8/ (199-10)	Exhibit 6 to the Declaration of Tom Steindler in Support of Defendant's Motion to Exclude Expert Testimony of Michael L. Metzker, Ph.D.	Entire document	DENIED (No supporting declaration filed. <i>Se</i> Civ. L.R. 79-5(e)(1).
Dkt. No. 200-9/ (199-11)	Exhibit 7 to the Declaration of Tom Steindler in Support of Defendant's Motion to Exclude Expert Testimony of Michael L. Metzker, Ph.D.	Entire document	<b>DENIED</b> (No supporting declaration filed. <i>Se</i> Civ. L.R. 79-5(e)(1).
Dkt. No. 200-10/ (199-12)	Exhibit 8 to the Declaration of Tom Steindler in Support of Defendant's Motion to Exclude Expert Testimony of Michael L. Metzker, Ph.D.	Entire document	<b>DENIED</b> (No supporting declaration filed. <i>Se</i> Civ. L.R. 79-5(e)(1).
	Dkt. No. 2	201 – DENIED	
Dkt. No. 202/ (201-4)	Defendant's Notice of Motion and Motion to Exclude Expert Testimony of Gregory K. Leonard, Ph.D.	Page 1:22–28 Page 2:1–16, 18–28 Page 3:1–13 Page 5:5–12, 15–24 Page 6, lines 15-28 Page 7, lines 1-3, 6-11	DENIED (No supporting declaration filed. Se Civ. L.R. 79-5(e)(1).
Dkt. No. 202-2/ (201-5)	Exhibit 1 to the Declaration of Tom Steindler in Support of Defendant's Motion to Exclude Expert Testimony of Gregory K. Leonard, Ph.D.	Entire document	<b>DENIED</b> (No supporting declaration filed. <i>Se</i> Civ. L.R. 79-5(e)(1)
Dkt. No. 202-3/ (201-6)	Exhibit 2 to the Declaration of Tom Steindler in Support of Defendant's Motion to Exclude Expert Testimony of Gregory K. Leonard, Ph.D.	Entire document	<b>DENIED</b> (No supporting declaration filed. <i>Se</i> Civ. L.R. 79-5(e)(1)
	•	203 – DENIED	
Dkt. No. 204/ (203-4)	Defendant's Notice of Motion and Motion to Preclude Certain Testimony of Dr. Susana	Page 1:20–25 Page 2:1, 4–25 Page 3:1–5 Page 7:21–23, 25–28	(No supporting declaration filed. <i>Se</i> Civ. L.R. 79-5(e)(1).

trict Court	District of California
d States District (	$\Box$
United	Vorthern

	T	T =	
	Ortiz-Urda Under <i>Daubert</i>	Š	
Dkt. No. 204-2/	Exhibit 1 to the	Entire document	DENIED
(203-5)	Declaration of Tom		(No supporting
	Steindler in Support of		declaration filed. See
	Defendant's Motion to		Civ. L.R. 79-5(e)(1).)
	Preclude Certain		
	Testimony of Dr. Susana		
	Ortiz-Urda Under <i>Daubert</i>		
Dkt. No. 204-3/	Exhibit 2 to the	Entire document	DENIED
(203-6)	Declaration of Tom		(No supporting
	Steindler in Support of		declaration filed. See
	Defendant's Motion to		Civ. L.R. 79-5(e)(1).)
	Preclude Certain		
	Testimony of Dr. Susana		
	Ortiz-Urda Under Daubert		
		205 – DENIED	
Dkt. No. 206/	Defendant's Notice of	Page 2:6–7, 21	DENIED
(205-4)	Motion and Motion to	Page 6:2–5, 18–20	(No supporting
	Exclude Expert Testimony		declaration filed. See
	of Ted Sweeney		Civ. L.R. 79-5(e)(1).)
Dkt. No. 206-2/	Exhibit 1 to the	Entire document	DENIED
(205-5)	Declaration of Tom		(No supporting
	Steindler in Support of		declaration filed. See
	Defendant's Motion to		Civ. L.R. 79-5(e)(1).)
	Exclude Expert Testimony		
	of Ted Sweeney		
	Dkt. No. 207 – GRANTED I		
Dkt. No. 208/	Plaintiff's Opposition to	Page 1:3–4, 6	GRANTED
(207-4)	Defendant's Motion to	Page 3:2–3, 22, 24	(Contains proprietary
	Strike Portions of Report	Page 4:4–5, 28	pharmaceutical
	of Plaintiff's Expert	Page 5:2–4	research and
	Michael L. Metzker,	Page 9:13–14, 16	development
	Ph.D.		information. See Dkt.
			No. 221.)
Dkt. No. 208-1/	Declaration of Laura E.	Page 2:3–4	GRANTED
(207-6)	Miller in Support of		(Contains proprietary
	Plaintiff's Opposition to		pharmaceutical
	Defendant's Motion to		research and
	Strike Portions of Report		development
	of Plaintiff's Expert		information. See Dkt.
	Michael L. Metzker,		No. 221.)
71. 37. 200 -	Ph.D.		CD A NEWS
Dkt. No. 208-5/	Exhibit 4 to the	Entire document	GRANTED
(207-8)	Declaration of Laura E.		(Contains proprietary
	Miller in Support of		pharmaceutical
	Plaintiff's Opposition to		research and
	Defendant's Motion to		development
	Strike Portions of Report		information. See Dkt.

United States District Court	Northern District of California
States Dist	District or
United	Northern

	T	1	T
	of Plaintiff's Expert Michael L. Metzker, Ph.D.		No. 221.)
Dkt. No. 208-10/ (207-10)	Exhibit 9 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Defendant's Motion to Strike Portions of Report of Plaintiff's Expert Michael L. Metzker, Ph.D.	Page 11:10–11, 14–16, 18–21 Page 14:27–28 Page 15:3–9	GRANTED (Contains proprietary pharmaceutical research and development information. See Dkt No. 221.)
Dkt. No. 208-14/ (207-12)	Exhibit 13 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Defendant's Motion to Strike Portions of Report of Plaintiff's Expert Michael L. Metzker, Ph.D.	Entire document	GRANTED (Contains trade secrets, as well as proprietary pharmaceutical research and development information. See Dkt No. 221.)
Dkt. No. 208-15/ (207-14)	Exhibit 14 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Defendant's Motion to Strike Portions of Report of Plaintiff's Expert Michael L. Metzker, Ph.D.	Page 10:13–16, 26 Page 31:11–17	<b>DENIED</b> (No supporting declaration filed. <i>See</i> Civ. L.R. 79-5(e)(1).
	Dkt. No. 209 – GRANTED	N PART and DENIED IN I	PART
Dkt. No. 210/ (209-4)	Plaintiff's Opposition to Novartis Pharmaceuticals Corporation's Motion for Judgment on the Pleadings	Page i:8–9 Page 2:7–9 Page 5:17–28 Page 6:1, 3–10, 18–22, 24–28 Page 7:1–2, 4 Page 8:6–13, 18–20 Page 9:3–4, 6–7, 9–10 Page 14:15–17 Page 15:4–5, 7–9, 11, 13–14 Page 17:4–11, 26–27 Page 21:23–25 Page 22:1–2	GRANTED IN PART (The following contains proprietary pharmaceutical research and development information:  • Page 6:5–10, 12 22, 24–28  • Page 7:1–2, 4 See Dkt. No. 223.)
Dkt. No. 210-6/ (209-6)	Exhibit 5 to the Declaration of Laura E. Miller in Support of	Entire document	GRANTED (Contains proprietary pharmaceutical

United States District Court Northern District of California 

	Plaintiff's Opposition to Novartis Pharmaceuticals Corporation's Motion for Judgment on the Pleadings		research and development information. <i>See</i> Dkt. No. 223.)
Dkt. No. 210-7/ (209-8)	Exhibit 6 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis Pharmaceuticals Corporation's Motion for Judgment on the Pleadings	Entire document	GRANTED (Contains proprietary pharmaceutical research and development information. See Dkt. No. 223.)
Dkt. No. 210-8/ (209-10)	Exhibit 7 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis Pharmaceuticals Corporation's Motion for Judgment on the Pleadings	Entire document	GRANTED (Contains proprietary pharmaceutical research and development information. <i>See</i> Dkt. No. 223.)
Dkt. No. 210-9/ (209-12)	Exhibit 8 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis Pharmaceuticals Corporation's Motion for Judgment on the Pleadings	Entire document	GRANTED (Contains proprietary pharmaceutical research and development information. See Dkt. No. 223.)
Dkt. No. 210-10/ (209-14)	Exhibit 9 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis Pharmaceuticals Corporation's Motion for Judgment on the Pleadings	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 210-11/ (209-16)	Exhibit 10 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis Pharmaceuticals Corporation's Motion for Judgment on the Pleadings	Entire document	<b>DENIED</b> (No supporting declaration filed. <i>See</i> Civ. L.R. 79-5(e)(1).)
Dkt. No. 210-12/ (209-18)	Exhibit 11 to the Declaration of Laura E. Miller in Support of	Entire document	<b>DENIED</b> (No supporting declaration filed. <i>See</i>

United States District Court	nern District of California
United	Northern D

	Plaintiff's Opposition to Novartis Pharmaceuticals Corporation's Motion for Judgment on the Pleadings		Civ. L.R. 79-5(e)(1).)
Dkt. No. 210-13/ (209-20)	Exhibit 12 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis Pharmaceuticals Corporation's Motion for Judgment on the Pleadings	Entire document	<b>DENIED</b> (No supporting declaration filed. <i>See</i> Civ. L.R. 79-5(e)(1).)
Dkt. No. 210-14/ (209-22)	Exhibit 13 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis Pharmaceuticals Corporation's Motion for Judgment on the Pleadings	Entire document  IN PART and DENIED IN 1	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 212/	Plaintiff's Opposition to	Page i:11–13	GRANTED IN
(211-4)	Defendant's Motion for Partial Summary Judgment	Page 1:3–5, 17, 19–21, 23, 28 Page 8:2, 4, 28 Page 9:1–4, 7, 24–28 Page 10:1, 7–13, 22–24, 26–28 Page 11:4, 7–9 Page 15:19 Page 16:12–13 Page 17:10–12	PART (The following contains proprietary pharmaceutical research and development information:  • Page i:11–13  • Page 1:3–5, 17, 23, 28  • Page 8:2, 4, 28  • Page 9:1–4, 24–28  • Page 10:1, 7–13, 22–24, 26–28  • Page 11:4, 7–9  • Page 15:19  • Page 16:12–13  See Dkt. No. 222.)
Dkt. No. 213-1/ (211-6)	Exhibit A to the Declaration of Michael L. Metzker in Support of Plaintiff's Opposition to Defendant's Motion for Partial Summary	Page 42:1–25 Page 43:1–6	<b>DENIED</b> (No supporting declaration filed. <i>See</i> Civ. L.R. 79-5(e)(1).)

rict Co	Callic
United States District Court	OTHER DISTRICT OF

	T1		<u> </u>
D1 11 010 0/	Judgment	D 10 17 16 06	CD ANDED IN
Dkt. No. 213-2/ (211-8)	Exhibit B to the Declaration of Michael L. Metzker in Support of Plaintiff's Opposition to Defendant's Motion for Partial Summary Judgment	Page 10:15–16, 26 Page 15:10–22, 14–16, 18–20, 26–27 Page 16:1, 18–20, 23–24 Page 27:17 Page 31:11–19 Page 46:20–21 Page 62:1, 3, 6–12, 14–15, 26 Page 63:1–4, 7–8, 26 Page 64:9–11 Page 65:2, 7–9, 11–12, 14, 18, 20–22 Page 66:23–26 Page 67:1–2, 4, 6–24 Page 106:1–3, 5, 11–12, 15–18	GRANTED IN PART (The following contains proprietary pharmaceutical research and development information:  Page 62:1, 3, 6–12, 14–15, 26  Page 63:1–4  Page 65:18  Page 66:23–26  Page 67:1–2, 4, 6–24  Page 106:1–3. See Dkt. No. 222.)
Dkt. No. 212-13/ (211-10)	Exhibit 12 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Defendant's Motion for Partial Summary Judgment	Entire document	<b>DENIED</b> (No supporting declaration filed. <i>See</i> Civ. L.R. 79-5(e)(1).)
Dkt. No. 212-20/	Exhibit 19 to the	Entire document	DENIED
(211-12)	Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Defendant's Motion for Partial Summary Judgment		(No supporting declaration filed. <i>See</i> Civ. L.R. 79-5(e)(1).)
Dkt. No. 214-1/	Exhibit A to the	Entire document	DENIED
(211-14)	Declaration of Jeffrey Winkler in Support of Plaintiff's Opposition to Defendant's Motion for Partial Summary Judgment		(No supporting declaration filed. <i>See</i> Civ. L.R. 79-5(e)(1).)
	Okt. No. 224 – GRANTED I	N PART and DENIED IN I	PART
Dkt. No. 325/ (224-4)	Plaintiff's Opposition to Defendant's Motion to Exclude Expert Testimony of Gregory K. Leonard, Ph.D.	Page 1:17–18 Page 4:6–7 Page 5:1	<b>DENIED</b> (No supporting declaration filed. <i>See</i> Civ. L.R. 79-5(e)(1).)
Dkt. No. 325-2/ (224-6)	Exhibit 1 to the Declaration of Laura E. Miller in Support of	Page 31, ¶¶ 62–63 Page 32, ¶¶ 63–65 Page 33, ¶¶ 65–66, n.88	GRANTED IN PART (The following

	Plaintiff's Opposition to Defendant's Motion to Exclude Expert Testimony of Gregory K. Leonard, Ph.D.	Page 34, ¶ 68 Page 35, ¶ 69, n.93, 95 Page 36, ¶ 70 Page 37, ¶ 72 Page 38, ¶¶ 72–73, n.102, 104 Page 39, ¶¶ 73–74, n.107 Page 40, n.110 Page 44, ¶ 81 Page 72, ¶¶ 124–125 Page 73, ¶ 125 Page 74, ¶ 128, n.219 Page 75, ¶¶ 128–129 Page 76, ¶¶ 131–132, n.222 Page 77, ¶¶ 132–135 Page 81, ¶ 147	contains proprietary pharmaceutical research and development information:  • Page 44, ¶ 81  • Page 71–72, ¶ 124  • Page 76, n.222  • Page 77, ¶¶ 133, 135  See Dkt. No. 237.)
Dkt. No. 325-3/ (224-8)	Exhibit 2 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Defendant's Motion to Exclude Expert Testimony of Gregory K. Leonard, Ph.D.	Page 45, n.133 Page 46, ¶ 74	<b>DENIED</b> (No supporting declaration filed. <i>See</i> Civ. L.R. 79-5(e)(1).)
	I .	226 – DENIED	
Dkt. No. 227/ (226-4)	Plaintiff's Opposition to Defendant's Motion to Preclude Certain Testimony of Dr. Susana Ortiz-Urda Under Daubert	Page 3:7–13, 16–21 Page 5:14–15, 21–24 Page 6:22–27 Page 9:8–10	DENIED (No supporting declaration filed. <i>See</i> Civ. L.R. 79-5(e)(1).)
Dkt. No. 227-2/ (226-6)	Exhibit 1 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Defendant's Motion to Preclude Certain Testimony of Dr. Susana Ortiz-Urda Under Daubert	Page 9, ¶ 20 Page 22, ¶ 50 Page 25, n.52 Page 26, ¶ 59, n.54 Page 27, ¶¶ 60, 61 Page 28, ¶ 63, n.61 Page 29, ¶ 66	<b>DENIED</b> (No supporting declaration filed. <i>See</i> Civ. L.R. 79-5(e)(1).)
Dkt. No. 227-3/ (226-8)	Exhibit 2 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Defendant's Motion to Preclude Certain Testimony of Dr. Susana Ortiz-Urda Under Daubert	Entire document	<b>DENIED</b> (No supporting declaration filed. <i>See</i> Civ. L.R. 79-5(e)(1).)

	ia
our	forni
nited States District Court	istrict of Calif
istri	of (
SO	trict
state	Dist
ed S	ern
Jnit	orthern
	ブ

	Dkt. No. 2	231 – DENIED	
Dkt. No. 233/	Defendant's Reply in	Page 1:15–17	DENIED
(231-4)	Support of Motion for	Page 2:6–7	(No supporting
	Partial Summary	Page 3:4–5	declaration filed. See
	Judgment	Page 6:5–8, 12–13, 21, 23–24 27–28	Civ. L.R. 79-5(e)(1).)
		Page 7:1–4, 8 13, 16, 26–28	
		Page 11:20–28	
		Page 12:8	
		Page 13:20–23	
		Page 15:8–10, 13–14, 17	
Dkt. No. 233-2/	Exhibit A to the	Pages 12–15	DENIED
(231-6)	Declaration of Thomas		(No supporting
	Steindler in Support of		declaration filed. See
	Reply in Support of		Civ. L.R. 79-5(e)(1).)
	Motion for Partial		
DI-4 NI 000 07	Summary Judgment	Ending 1	DENIED
Dkt. No. 233-3/	Exhibit B to the	Entire document	DENIED (No supporting
(231-7)	Declaration of Thomas Steindler in Support of		(No supporting declaration filed. <i>See</i>
	Reply in Support of		Civ. L.R. 79-5(e)(1).)
	Motion for Partial		CIV. L.K. 79-3(C)(1).)
	Summary Judgment		
Dkt. No. 233-4/	Exhibit C to the	Entire document	DENIED
(231-8)	Declaration of Thomas	Entire document	(No supporting
(201 0)	Steindler in Support of		declaration filed. See
	Reply in Support of		Civ. L.R. 79-5(e)(1).)
	Motion for Partial		
	Summary Judgment		
Dkt. No. 233-5/	Exhibit D to the	Entire document	DENIED
(231-9)	Declaration of Thomas		(No supporting
	Steindler in Support of		declaration filed. See
	Reply in Support of		Civ. L.R. 79-5(e)(1).)
	Motion for Partial		
DI-4 N. 222 61	Summary Judgment	Entire de	DENIED
Dkt. No. 233-6/	Exhibit E to the	Entire document	DENIED (No supporting
(231-10)	Declaration of Thomas		(No supporting
	Steindler in Support of		declaration filed. See
	Reply in Support of Motion for Partial		Civ. L.R. 79-5(e)(1).)
	Summary Judgment		
		232 – DENIED	
Dkt. No. 234/	Plaintiff's Opposition to	Page 3:25–28	DENIED
(232-4)	Defendant's Motion to	Page 4:1–2, 5–20	(No supporting
,	Exclude Expert Testimony	Page 6:7	declaration filed. See
	of Ted Sweeney	Page 7:24–25	Civ. L.R. 79-5(e)(1).)
		Page 8:11–14, 23, 28	

	B
ourt	orni
ŭ	alif
United States District Court	District of California
Dis	ict c
ates	istri
St	n D
itec	orthern
$\overline{\Box}$	Vor

		Page 9:15, 28	
		Page 11:21, 27–28	
		Page 12:17, 28	
		Page 13:5–7, 12–13, 26	
Dkt. No. 234-3/	Exhibit 2 to the	Page 13:12–13, 15–26	DENIED
(232-6)	Declaration of Laura E.	Page 14:5, 7–17	(No supporting
	Miller in Support of	Page 23:22–23	declaration filed. See
	Plaintiff's Opposition to	Page 24:7–12	Civ. L.R. 79-5(e)(1).)
	Defendant's Motion to	Page 25:16–27	
	Exclude Expert Testimony	Page 26:1–10, 12–14	
D1 . N. 004.5/	of Ted Sweeney	P. d. 1	DENHED
Dkt. No. 234-5/	Exhibit 4 to the	Entire document	DENIED
(232-8)	Declaration of Laura E.		(No supporting
	Miller in Support of		declaration filed. See
	Plaintiff's Opposition to		Civ. L.R. 79-5(e)(1).)
	Defendant's Motion to		
	Exclude Expert Testimony		
Dkt. No. 234-6/	of Ted Sweeney Exhibit 5 to the	Page 1:19–21, 23–26, 28	DENIED
(232-10)	Declaration of Laura E.	Page 2:1–3, 6–7, 12–16,	(No supporting
(232 10)	Miller in Support of	27–28	declaration filed. See
	Plaintiff's Opposition to	Page 3:1–3, 11–12	Civ. L.R. 79-5(e)(1).)
	Defendant's Motion to	Page 4:3, 5	Civ. E.it. 75 5(c)(1).)
	Exclude Expert Testimony	Page 5:17–18	
	of Ted Sweeney	Page 6:15–16	
		Page 7:19–27	
		Page 8:1–2, 10–15	
	Dkt. No. 2	235 – DENIED	
Dkt. No. 236/	Plaintiff's Motion to	Page 4:27–28	DENIED
(235-4)	Strike Defendant's	Page 5:1	(No supporting
	Daubert Motions Filed		declaration filed. See
	June 6, 2019		Civ. L.R. 79-5(e)(1).)
Dkt. No. 236-2/	Exhibit 1 to the	Entire document	DENIED
(235-6)	Declaration of Laura E.		(No supporting
	Miller in Support of		declaration filed. See
	Plaintiff's Motion to		Civ. L.R. 79-5(e)(1).)
	Strike Defendant's		
	Daubert Motions Filed		
	June 6, 2019		
Dkt. No. 236-3/	Exhibit 2 to the	Entire document	DENIED
(235-8)	Declaration of Laura E.		(No supporting
	Miller in Support of		declaration filed. See
	Plaintiff's Motion to		Civ. L.R. 79-5(e)(1).)
	Strike Defendant's		
	Daubert Motions Filed		
	June 6, 2019  Dkt No. 24	   <del> </del> 	
Dkt. No. 242-3/	Exhibit 5 to the	Entire document	GRANTED
∠R., 110, ∠⊤∠ J/			Jamileo

United States District Court Northern District of California
---

(Native Excel File)	Declaration of Tom Steindler in Support of Defendant's Reply in		(Contains licensing and proprietary pharmaceutical
	Support of Motion to Preclude Certain		research and development
	Testimony of Dr. Susana		information. See Dkt
	Ortiz-Urda Under <i>Daubert</i>		No. 242.)
	I .	258 – DENIED	/
Dkt. No. 259/	Plaintiff's Motion In	Page 1:24–28	DENIED
(258-4)	Limine No. 1 Excluding	Page 2:1–3, 15–18	(No supporting
	Undisclosed Validity	Page 3:1–3	declaration filed. See
	Challenges		Civ. L.R. 79-5(e)(1).
Dkt. No. 259-2/	Exhibit 1 to the	Entire document	DENIED
(258-6)	Declaration of Laura E.		(No supporting
	Miller in Support of Plaintiff's Motion in		declaration filed. See
	Limine No. 1 Excluding		Civ. L.R. 79-5(e)(1).)
	Undisclosed Validity		
	Challenges		
Dkt. No. 259-3/	Exhibit 2 to the	Entire document	DENIED
(258-8)	Declaration of Laura E.		(No supporting
( )	Miller in Support of		declaration filed. See
	Plaintiff's Motion in		Civ. L.R. 79-5(e)(1).
	Limine No. 1 Excluding		
	Undisclosed Validity		
	Challenges		
		261 – DENIED	T
Dkt. No. 262/	Plaintiff's Motion In	Page 1:8–9	DENIED
(261-4)	Limine No. 3 Re:	Page 2:2–22	(No supporting
	Cumulative Expert	Page 3:2–3	declaration filed. See
Dkt. No. 262-2/	Testimony Exhibit 1 of the	Entire document	Civ. L.R. 79-5(e)(1).) <b>DENIED</b>
(261-6)	Declaration Of Laura E.	Entire document	(No supporting
(201-0)	Miller In Support Of		declaration filed. See
	Plaintiff's Motion In		Civ. L.R. 79-5(e)(1).)
	Limine No. 3 Re:		
	Cumulative Expert		
	Testimony		
Dkt. No. 262-3/	Exhibit 2 of the	Entire document	DENIED
(261-8)	Declaration Of Laura E.		(No supporting
	Miller In Support Of		declaration filed. See
	Plaintiff's Motion In		Civ. L.R. 79-5(e)(1).)
	Limine No. 3 Re:		
	Cumulative Expert		
Dkt. No. 262-4/	Testimony Exhibit 3 of the	Entire document	DENIED
(261-10)	Declaration Of Laura E.	Entire document	(No supporting
(201-10)	Deciaration of Laura E.		i (140 supporting

ed States District Court	ern District of California
United S	Northern ]

	Plaintiff's Motion In Limine No. 3 Re: Cumulative Expert Testimony		Civ. L.R. 79-5(e)(1).
Dkt. No. 262-5/ (261-12)	Exhibit 4 of the Declaration Of Laura E. Miller In Support Of Plaintiff's Motion In Limine No. 3 Re: Cumulative Expert Testimony	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).
Dkt. No. 262-6/ (261-14)	Exhibit 5 of the Declaration Of Laura E. Miller In Support Of Plaintiff's Motion In Limine No. 3 Re: Cumulative Expert Testimony	Entire document	<b>DENIED</b> (No supporting declaration filed. <i>Sec</i> Civ. L.R. 79-5(e)(1).
	·	263 – DENIED	
Dkt. No. 264/	Plaintiff's Motion In	Page 2:25–28	DENIED
(263-4)	Limine No. 4 re: Excluding Withheld Evidence	Page 3:1–3 Page 3:7–9 Page 4:28 Page 5:1	(No supporting declaration filed. <i>Se</i> Civ. L.R. 79-5(e)(1).
Dkt. No. 264-1/ (263-6)	Declaration of Laura E. Miller In Support of Plaintiff's Motion In Limine No. 4 re: Excluding Withheld Evidence	Page 1:17–19	DENIED (No supporting declaration filed. Se Civ. L.R. 79-5(e)(1).
Dkt. No. 264-6/ (263-8)	Exhibit 5 to the Declaration of Laura E. Miller In Support of Plaintiff's Motion In Limine No. 4 re: Excluding Withheld Evidence	Entire document	<b>DENIED</b> (No supporting declaration filed. <i>Se</i> Civ. L.R. 79-5(e)(1).
Dkt. No. 264-7/ (263-10)	Exhibit 6 to the Declaration of Laura E. Miller In Support of Plaintiff's Motion In Limine No. 4 re: Excluding Withheld Evidence	Entire document	DENIED  (No supporting declaration filed. <i>Se</i> Civ. L.R. 79-5(e)(1).
		265 – GRANTED	<u>'</u>
Dkt. No. 266/ (265-4)	Plaintiff's Motion in Limine No. 5 re: Excluding Hidden	Page 1:20–25 Page 2:2–3, 7–9	GRANTED (Contains proprietary pharmaceutical

strict Court	of California
United States District (	Northern District of

	Hearsay Testimony		research and
	Tlearsay Testimony		development
			information. See Dk
			No. 274.)
Dkt. No. 266-2/	Exhibit 1 to the	Entire document	GRANTED
	Declaration of Laura E.	Entire document	
(265-6)			(Contains proprietary
	Miller in support of Plaintiff's Motion in		pharmaceutical research and
	Limine No. 5 re:		
			development information. <i>See</i> Dk
	Excluding Hidden		
	Hearsay Testimony		No. 274.)
		IN PART and DENIED IN I	
Dkt. No. 273-5/	Exhibit E to the	Entire document	GRANTED
(267-5)	Declaration of Thomas P.		(Contains proprietary
	Steindler In Support of		pharmaceutical
	Novartis's Motions in		research and
	Limine		development
			information. See Dk
DI . N. 070 (/	P 1312 P 4	D : 11 12	No. 267-1.)
Dkt. No. 273-6/	Exhibit F to the	Page i:11–13	GRANTED IN
(267-7)	Declaration of Thomas P.	Page 1:3–5, 17, 19–21, 23,	PART
	Steindler In	28	(The following
	Support of Novartis's	Page 8:2, 4, 28	contains proprietary
	Motions in Limine	Page 9:1–4, 7, 24–28	pharmaceutical
		Page 10:1, 7–13, 22–24,	research and
		26–28	development
		Page 11:4, 7–9	information:
		Page 15:19	• Page i:11–13
		Page 16:12–13 Page 17:10–12	• Page 1:3–5, 17, 23, 28
			• Page 8:2, 4, 28
			• Page 9:1–4, 24–
			28
			• Page 10:1, 7–13
			22–24, 26–28
			• Page 11:4, 7–9
			• Page 15:19
			• Page 16:12–13
			See Dkt. No. 222.)
Dkt. No. 273-7/	Exhibit G to the	Page i:8–9	GRANTED IN
(267-9)	Declaration of Thomas P.	Page 2:7–9	PART
S	Steindler In	Page 5:17–28	(The following
	Support of Novartis's	Page 6:1, 3–10, 18–22,	contains proprietary
	Motions in Limine	24–28	pharmaceutical
		Page 7:1–2, 4	research and
		Page 8:6–13, 18–20	development
		Page 9:3–4, 6–7, 9–10	information:
		1 age 7.3-4, 0-7, 7-10	minorimation.

Dkt. No. 273-11/ (267-10)  Dkt. No. 272/ (267-4)	Exhibit K to the Declaration of Thomas P. Steindler In Support of Novartis's Motions in Limine Novartis's Motion in Limine No. 5 re: Evidence or Argument Suggesting Damages Should Be Awarded for Any Period After December 2018	Page 15:4–5, 7–9, 11, 13–14 Page 17:4–11, 26–27 Page 21:23–25 Page 22:1–2 Entire document  Page 1:12–26 Page 2:25–26	22, 24–28 • Page 7:1–2, 4 See Dkt. No. 223.)  DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)  DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
		<u> </u> 282 – DENIED	
Dkt. No. 283/ (282-4)	Opposition To Plexxikon's Motion in Limine No. 1 re: Excluding Undisclosed Validity Challenges	Page 2:12–13, 19–20, 23–24 Page 3:5–8	DENIED (No supporting declaration filed. <i>See</i> Civ. L.R. 79-5(e)(1).)
		285 – DENIED	T
Dkt. No. 286-2/ (285-4)	Exhibit A to the Declaration of Thomas P. Steindler In Support of Opposition To Plexxikon's Motion in Limine No. 3 re: Cumulative Expert Testimony	¶¶ 3, 7, 17, 21, 25, 26, 28–31, 75–78, 115–122, 126, 127	<b>DENIED</b> (No supporting declaration filed. <i>See</i> Civ. L.R. 79-5(e)(1).)
Dkt. No. 286-7/ (285-6)	Exhibit F to the Declaration of Thomas P. Steindler In Support of Opposition To Plexxikon's Motion in Limine No. 3 re: Cumulative Expert Testimony	¶ 3	<b>DENIED</b> (No supporting declaration filed. <i>See</i> Civ. L.R. 79-5(e)(1).)
Dkt. No. 286-9/ (285-8)	Exhibit H to the Declaration of Thomas P. Steindler In Support of Opposition To Plexxikon's Motion in Limine No. 3 re: Cumulative Expert Testimony	¶¶ 61–65	<b>DENIED</b> (No supporting declaration filed. <i>See</i> Civ. L.R. 79-5(e)(1).)

t	iia
x Cour	ct of California
S District Cor	et of Calife
tates ]	<b>Distri</b>
Jnited States D	rthern I
$\Box$	Nor

Dkt. No. 286-10/	Exhibit I to the	¶¶ 57–59, 77–80	DENIED
(285-10)	Declaration of Thomas P.		(No supporting
	Steindler In Support of		declaration filed. See
	Opposition To		Civ. L.R. 79-5(e)(1).
	Plexxikon's Motion in		
	Limine No. 3 re:		
	Cumulative Expert		
	Testimony		
		287 – DENIED	
Dkt. No. 288-3/	Exhibit B to the	Entire document	DENIED
(287-3)	Declaration of		(Defendant states, in
	Thomas P. Steindler In		conclusory fashion,
	Support Of Novartis's		that the document
	Opposition to Plexxikon's		"contain[s] and
	Motion in Limine No. 4		refer[s] to
	re: Excluding Withheld		competitively
	Evidence		sensitive documents
			the public disclosure
			of which would caus
			harm to Novartis."
			See Dkt. No. 287-1.
			This generic
			explanation is
			insufficient to
			establish good cause
Dkt. No. 288-4/	Exhibit C to the	Entire document	DENIED
(287-4)	Declaration of		(Defendant states, in
	Thomas P. Steindler In		conclusory fashion,
	Support Of Novartis's		that the document
	Opposition to Plexxikon's		"contain[s] and
	Motion in Limine No. 4		refer[s] to
	re: Excluding Withheld		competitively
	Evidence		sensitive documents
			the public disclosure
			of which would caus
			harm to Novartis."
			See Dkt. No. 287-1.
			This generic
			explanation is
			insufficient to
	DIANI AND ODANIED I		establish good cause
Dkt. No. 290/	Okt. No. 289 – GRANTED I		GRANTED
	Opposition To Plexxikon's Motion in	Page 1:21–23;	
(289-4)		Page 2:20–25;	(Contains proprietary
Limine No. 5 re:		Page 3:1–8;	pharmaceutical
	Excluding Hidden	Page 5:3	research and
	Hearsay Testimony		development information. <i>See</i> Dk

strict Court	of California
Inited States District Co	orthern District of Calif

	T		No. 201.)
Dl-4 No. 200 2/	Embilit A to the	Entine de comment	No. 301.) <b>DENIED</b>
Dkt. No. 290-2/	Exhibit A to the	Entire document	·
(289-5)	Declaration of		(No supporting
	Thomas P. Steindler In		declaration filed. See
	Support of Opposition To		Civ. L.R. 79-5(e)(1).)
	Plexxikon's Motion in		
	Limine No. 5 re:		
	Excluding Hidden		
	Hearsay Testimony	101 DENIED	
D1 : N 202/	1	291 – DENIED	DENTED
Dkt. No. 292/	Plaintiff's Opposition to	Page 2:7–10	DENIED
(291-3)	Novartis's Motion in		(No supporting
	Limine No. 1 Re: PTAB		declaration filed. See
	Proceedings		Civ. L.R. 79-5(e)(1).)
Dkt. No. 292-6/	Exhibit 5 to the	Entire document	DENIED
(291-5)	Declaration of Laura E.		(No supporting
	Miller in Support of		declaration filed. See
	Plaintiff's Opposition to		Civ. L.R. 79-5(e)(1).)
	Novartis's Motion in		
	Limine No. 1 Re: PTAB		
	Proceedings		
Dkt. No. 292-8/	Exhibit 7 to the	Entire document	DENIED
(291-7)	Declaration of Laura E.		(No supporting
	Miller in Support of		declaration filed. See
	Plaintiff's Opposition to		Civ. L.R. 79-5(e)(1).)
	Novartis's Motion in		
	Limine No. 1 Re: PTAB		
	Proceedings		
Dkt. No. 292-9/	Exhibit 8 to the	Entire document	DENIED
(291-9)	Declaration of Laura E.		(No supporting
,	Miller in Support of		declaration filed. See
	Plaintiff's Opposition to		Civ. L.R. 79-5(e)(1).)
	Novartis's Motion in		
	Limine No. 1 Re: PTAB		
	Proceedings		
		293 – DENIED	
Dkt. No. 294/	Plaintiff's Opposition to	Page 2:3–5, 11–16	DENIED
(293-3)	Novartis's Motion in		(No supporting
( /	Limine No. 2 re:		declaration filed. See
	Unasserted Patents as		Civ. L.R. 79-5(e)(1).)
	Evidence of the Validity		
	of the Asserted Patents		
Dkt. No. 294-3/	Exhibit 2 to the	Entire document	DENIED
(293-5)	Declaration of Laura E.	Little document	(No supporting
(473-3)	Miller in Support of		declaration filed. See
	1		
	Plaintiff's Opposition to Novartis's Motion in		Civ. L.R. 79-5(e)(1).)
	Limine No. 2 re:		
	Lilling No. 2 fe:		

	Unasserted Patents as		
	Evidence of the Validity		
	of the Asserted Patents		
Dkt. No. 294-5/	Exhibit 4 to the	Entire document	DENIED
(293-7)	Declaration of Laura E.		(No supporting
	Miller in Support of		declaration filed. See
	Plaintiff's Opposition to		Civ. L.R. 79-5(e)(1).)
	Novartis's Motion in		
	Limine No. 2 re:		
	Unasserted Patents as		
	Evidence of the Validity		
	of the Asserted Patents		
	I .	295 – DENIED	
Dkt. No. 296-2/	Exhibit 1 to the	Entire document	DENIED
(295-3)	Declaration of Laura E.		(No supporting
,	Miller in Support of		declaration filed. See
	Plaintiff's Opposition to		Civ. L.R. 79-5(e)(1).)
	Novartis's Motion in		
	Limine No. 3 re: Evidence		
	or Argument		
	Mischaracterizing or		
	Having a Tendency to		
	Mislead as to the Scope of		
	Plexxikon's Patent Rights		
Dkt. No. 296-3/	Exhibit 2 to the	Entire document	DENIED
(295-5)	Declaration of Laura E.		(No supporting
,	Miller in Support of		declaration filed. See
	Plaintiff's Opposition to		Civ. L.R. 79-5(e)(1).)
	Novartis's Motion in		
	Limine No. 3 re: Evidence		
	or Argument		
	Mischaracterizing or		
	Having a Tendency to		
	Mislead as to the Scope of		
	Plexxikon's Patent Rights		
	Dkt. No. 297 – GRANTED I	N PART and DENIED IN	PART
Dkt. No. 326/	Plaintiff's Opposition to	Page 1:19–24	GRANTED
(297-4)	Novartis's Motion in	Page 2:9, 17–28	(Contains licensing
	Limine No. 4 Re: Alleged	Page 3:1–5, 8–20	negotiation, as well as
	Copying	_	proprietary
			pharmaceutical
			research and
			development
			information. See Dkt.
			No. 302.)
D1 : N1 . 00 ( 0 /		Entine de coment	· · · · · · · · · · · · · · · · · · ·
Dkt. No. 326-2/	Exhibit 1 to the	Entire document	GRANTED
Dkt. No. 326-2/ (297-6)	Exhibit 1 to the Declaration of Laura E.	Entire document	
		Entire document	(Contains proprietary pharmaceutical

nr	rnia
States District Court	District of Californi
Distri	ct of
States	Distri
United 5	orthern
$\bar{\Box}$	Š

	Plaintiff's Opposition to Novartis's Motion in Limine No. 4 Re: Alleged Copying		research and development information. <i>See</i> Dkt. No. 302.)
Dkt. No. 326-3/ (297-8)	Exhibit 2 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis's Motion in Limine No. 4 Re: Alleged Copying	Entire document	GRANTED (Contains proprietary pharmaceutical research and development information. See Dkt No. 302.)
Dkt. No. 316/ (297-10)	Exhibit 3 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis's Motion in Limine No. 4 Re: Alleged Copying	Entire document	GRANTED (Contains licensing negotiation, as well as proprietary pharmaceutical research and development information. See Dkt. No. 302.)
Dkt. No. 298-5/ (297-12)	Exhibit 4 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis's Motion in Limine No. 4 Re: Alleged Copying	Entire document	GRANTED (Contains licensing negotiation, as well as proprietary pharmaceutical research and development information. See Dkt No. 302.)
Dkt. No. 298-6/ (297-14)	Exhibit 5 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis's Motion in Limine No. 4 Re: Alleged Copying	Entire document	<b>DENIED</b> (No supporting declaration filed. <i>See</i> Civ. L.R. 79-5(e)(1).)
Dkt. No. 298-7/ (297-16)	Exhibit 6 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis's Motion in Limine No. 4 Re: Alleged Copying	Entire document	<b>DENIED</b> (No supporting declaration filed. <i>See</i> Civ. L.R. 79-5(e)(1).)
Dkt. No. 298-8/ (297-18)	Exhibit 7 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis's Motion in	Entire document	(No supporting declaration filed. <i>See</i> Civ. L.R. 79-5(e)(1).)

<del>L</del>	nia
Cour	lifori
States District Co	of Calif
s Dis	strict of
State	Dist
nited	rtherr
5	Noi

	Limine No. 4 Re: Alleged		
	Copying	200 DENIED	
DI. N. 207.4/		299 – DENIED	DENHED
Dkt. No. 327-4/ (299-4)	Exhibit 3 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis's Motion in Limine No. 5 Re: Evidence or Argument Suggesting Damages Should be Awarded for Any Period After December 2018	Entire document	<b>DENIED</b> (No supporting declaration filed. <i>Se</i> Civ. L.R. 79-5(e)(1).
Dkt. No. 327-5/ (299-6)	Exhibit 4 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis's Motion in Limine No. 5 Re: Evidence or Argument Suggesting Damages Should be Awarded for Any Period After December 2018  Dkt. No. 306 – GRANTED I	N PART and DENIED IN	DENIED (No supporting declaration filed. Se Civ. L.R. 79-5(e)(1).
Dkt. No. 307/ (306-4)	Defendant's Notice of Motion and Motion to Strike Second Supplemental Report of Plaintiff's Expert Gregory K. Leonard, Ph.D.	Page:2:25-28 Page 6:25-26 Page 8:11 Page 9:10, 17-26 Page 10:1-14, 24-28 Page 11:1-14, 16-18 Page 13:4-10 Page 14:22-23 Page 15:1-9, 17-20 Page 16:4, 7-11, 20-22, 24-27 Page 17:1-8	(No supporting declaration filed. Se Civ. L.R. 79-5(e)(1).
Dkt. No. 307-2/ (306-5)	Exhibit 1 to the Declaration of Thomas P. Steindler In Support Of Defendant's Motion To Strike Second Supplemental Report of Plaintiff's Expert Gregory K. Leonard, Ph.D.	Entire document	<b>DENIED</b> (No supporting declaration filed. <i>Se</i> Civ. L.R. 79-5(e)(1).
	· · · · · · · · · · · · · · · · · · ·	¶50 % n 75	CDANTED
Dkt. No. 307-3/	Exhibit 2 to the	¶ 59, & n.75	GRANTED

			,
	Steindler In Support Of	¶¶ 75–77, & n.112, 115,	negotiation terms.
	Defendant's Motion To	117	See Dkt. No. 312.)
	Strike Second	¶ 79, & n.118	
	Supplemental Report of	¶¶ 112–114, & n.194	
	Plaintiff's Expert Gregory	Exhibit 3 (pages 1 and 2)	
	K. Leonard, Ph.D.		
Dkt. No. 307-4/	Exhibit 3 to the	Entire document	DENIED
(306-8)	Declaration of Thomas P.		(No supporting
	Steindler In Support Of		declaration filed. See
	Defendant's		Civ. L.R. 79-5(e)(1).)
	Motion To Strike Second		
	Supplemental Report of		
	Plaintiff's Expert Gregory		
	K. Leonard, Ph.D.		
]	Dkt. No. 314 – GRANTED I	N PART and DENIED IN I	PART
Dkt. No. 325/	Plaintiff's Opposition to	Page 3:16–22, 23–24, 26	GRANTED
(314-5)	Defendant's Motion to		(Contains trade
	Exclude Expert Testimony		secrets and licensing
	of Gregory K. Leonard,		negotiation terms.
	Ph.D.		See Dkt. No. 314.)
Dkt. No. 325/	Plaintiff's Opposition to	Page 1:17–18	DENIED
(314-5)	Defendant's Motion to	Page 2:3–13	(No supporting
	Exclude Expert Testimony	Page 4:6–7	declaration filed. See
	of Gregory K. Leonard,	Page 5:1	Civ. L.R. 79-5(e)(1).)
	Ph.D.	Tage 3.1	CIV. L.R. 77-3(c)(1).)
Dkt. No. 325-2/	Exhibit 1 to the	Page 29, ¶ 59	GRANTED
(314-7)	Declaration of Laura E.	Page 40, ¶ 79	(Contains trade
(= )	Miller in Support of	Page 41, n.112	secrets and licensing
	Plaintiff's Opposition to	Page 42, n.117, 118	negotiation terms.
	Defendant's Motion to	Page 44, ¶ 83	See Dkt. No. 314.)
	Exclude Expert Testimony	Page 45, ¶¶ 83–85	
	of Gregory K. Leonard,	Page 46, ¶¶ 85–86, n.132–	
	Ph.D.	134	
		Page 47, ¶¶ 86–88, n.135	
		Page 48, ¶¶ 88–89, n.139–	
		140	
		Page 58, ¶¶ 102, 104	
		Page 59, ¶ 104	
		Page 60, ¶¶ 106–107	
		Page 61, ¶¶ 107–109,	
		n.185	
		Page 62, ¶¶ 109–110,	
		n.188	
		Page 65, ¶¶ 113–114,	
		n.194	
		Page 66, ¶ 114	
		Page 81, ¶ 144, n.231	
	1	1 agc 01,    144, 11.231	

ırt	mia
t Cour	California
1 States District (	Calif
istr	of (
S	strict of
ate	ist
St	пГ
nited	orthern
$C_{n}$	lort
	4

Dkt. No. 325-2/ (314-7)	Exhibit 1 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Defendant's Motion to Exclude Expert Testimony of Gregory K. Leonard, Ph.D.	Page 28, ¶ 57 Page 29, ¶ 60 Page 30, Figure 4 Page 31, ¶¶ 62–63 Page 32, ¶¶ 63–65 Page 33, ¶¶ 65–66, n.88 Page 34, ¶ 68 Page 35, ¶¶ 68–69, n.93, 95 Page 36, ¶ 70 Page 37, ¶ 72 Page 38, ¶¶ 72–73, n.102, 104 Page 39, ¶¶ 73–74, n.107 Page 40, n.110 Page 44, ¶ 81 Page 68, ¶¶ 117–118 Page 69, ¶¶ 119–120 Page 70, ¶¶ 120–121 Page 71, ¶¶ 122–123 Page 72, ¶¶ 124–125 Page 73, ¶¶ 126–127 Page 74, ¶¶ 127–128, n.219 Page 75, ¶¶ 128–131 Page 76, ¶¶ 131–132, n.222 Page 77, ¶¶ 132–135	GRANTED IN PART (The following contains proprietary pharmaceutical research and development information:  • Page 44, ¶ 81  • Page 68, ¶¶ 117–118  • Page 69, ¶¶ 119–120  • Page 70, ¶¶ 120–121  • Page 71, ¶¶ 122–123  • Page 72, ¶¶ 124–125  • Page 73, ¶¶ 126–127  • Page 74, ¶¶ 127–128, n.219  • Page 75, ¶¶ 128–131  • Page 76, ¶¶ 131–132, n.222  • Page 77, ¶¶ 132–135  See Dkt. No. 330.)
Dkt. No. 316/ (314-9)	Exhibit 3 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis's Motion in Limine No. 4 Re: Alleged Copying	Page 44, ¶ 83	GRANTED (Contains trade secret and licensing negotiation terms.  See Dkt. No. 314.)
Dkt. No. 327-2/ (314-11)	Exhibit 1 to the Declaration of Laura E. Miller in Support of Plexxikon's Opposition to Novartis's Motion in Limine No. 5 Re: Evidence or Argument Suggesting Damages Should be Awarded for Any Period After December 2018	Page 2:20–27 Page 3:1–28 Page 4:1–2, 4–27 Page 5:8–9	GRANTED (Contains trade secret and licensing negotiation terms.  See Dkt. No. 314.)

	a
Court	forni
C T	alif
stric	District of Calif
Z.	ict
United States District (	)istı
d St	Н
nite	Vorthern
	9

Dkt. No. 327-3/ (314-13)	Exhibit 2 to the Declaration of Laura E. Miller in Support of Plexxikon's Opposition to	Page 14:8–10	GRANTED (Contains trade secret and licensing negotiation terms.
	Novartis's Motion in Limine No. 5 Re: Evidence or Argument Suggesting Damages Should be Awarded for Any Period After December 2018		See Dkt. No. 314.)
Dkt. No. 327-4/ (314-15)	Exhibit 3 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis's Motion in Limine No. 5 Re: Evidence or Argument Suggesting Damages Should be Awarded for Any Period After December 2018	Page 65, ¶ 113 Page 66, ¶ 114	GRANTED (Contains trade secret and licensing negotiation terms. See Dkt. No. 314.)
Dkt. No. 327-4/ (314-15)	Exhibit 3 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis's Motion in Limine No. 5 Re: Evidence or Argument Suggesting Damages Should be Awarded for Any Period After December 2018	Page 27, ¶ 56 Page 27–28, ¶ 57	<b>DENIED</b> (No supporting declaration filed. <i>See</i> Civ. L.R. 79-5(e)(1).)
Dkt. No. 327-5/ (314-17)	Exhibit 4 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis's Motion in Limine No. 5 Re: Evidence or Argument Suggesting Damages Should be Awarded for Any Period After December 2018	Exhibits 2a, 2b, 3, and 4	GRANTED (Contains trade secret and licensing negotiation terms. See Dkt. No. 314.)
Dkt. No. 327-5/ (314-17)	Exhibit 4 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to	Page 1–2, ¶ 4 Exhibits 5a, 5b, 5c, and 6	DENIED (No supporting declaration filed. <i>See</i> Civ. L.R. 79-5(e)(1).)

United States District Court Northern District of California
---

	Novartis's Motion in		
	Limine No. 5 Re:		
	Evidence or Argument		
	Suggesting Damages		
	Should be Awarded for		
	Any Period After		
	December 2018		
Dkt. No. 319/	Exhibit 4 to the	Page 2:20–27	GRANTED
(314-19)	Declaration of Thomas P.	Page 3:1–28	(Contains trade secret
	Steindler in Support of	Page 4:1–2, 4–27	and licensing
	Defendant's Motion to	Page 5:8–9	negotiation terms.
	Strike Second		See Dkt. No. 314.)
	Supplemental Report of		,
	Plaintiff's Expert Gregory		
	K. Leonard, Ph.D.		
Dkt. No. 319/	Exhibit 4 to the	Page 6:2–3	DENIED
(314-19)	Declaration of Thomas P.		(No supporting
	Steindler in Support of		declaration filed. See
	Defendant's Motion to		Civ. L.R. 79-5(e)(1).)
	Strike Second		
	Supplemental Report of		
	Plaintiff's Expert Gregory		
	K. Leonard, Ph.D.		
	Dkt. No. 332 – GRANTED 1	N PART and DENIED IN	PART
Dkt. No. 333/	Dkt. No. 332 – GRANTED I Plaintiff's Opposition to	N PART and DENIED IN Page 6:26–27	PART DENIED
Dkt. No. 333/	Plaintiff's Opposition to	Page 6:26–27	DENIED
Dkt. No. 333/	Plaintiff's Opposition to Novartis's Motion to	Page 6:26–27	<b>DENIED</b> (No supporting
Dkt. No. 333/ (332-4)	Plaintiff's Opposition to Novartis's Motion to Strike the Second Supplemental Report of Dr. Gregory K. Leonard	Page 6:26–27	DENIED (No supporting declaration filed. See
Dkt. No. 333/	Plaintiff's Opposition to Novartis's Motion to Strike the Second Supplemental Report of	Page 6:26–27 Page 16:20–21 Page 2:20–27	DENIED (No supporting declaration filed. See
Dkt. No. 333/ (332-4)	Plaintiff's Opposition to Novartis's Motion to Strike the Second Supplemental Report of Dr. Gregory K. Leonard Exhibit 3 to the Declaration of Laura E.	Page 6:26–27 Page 16:20–21	(No supporting declaration filed. <i>See</i> Civ. L.R. 79-5(e)(1).)
Dkt. No. 333/ (332-4) Dkt. No. 333-4/	Plaintiff's Opposition to Novartis's Motion to Strike the Second Supplemental Report of Dr. Gregory K. Leonard Exhibit 3 to the Declaration of Laura E. Miller in Support of	Page 6:26–27 Page 16:20–21 Page 2:20–27	DENIED (No supporting declaration filed. <i>See</i> Civ. L.R. 79-5(e)(1).)  GRANTED
Dkt. No. 333/ (332-4) Dkt. No. 333-4/	Plaintiff's Opposition to Novartis's Motion to Strike the Second Supplemental Report of Dr. Gregory K. Leonard Exhibit 3 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to	Page 6:26–27 Page 16:20–21 Page 2:20–27 Pages 3–4	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)  GRANTED (Contains trade secret and licensing negotiation terms.
Dkt. No. 333/ (332-4) Dkt. No. 333-4/	Plaintiff's Opposition to Novartis's Motion to Strike the Second Supplemental Report of Dr. Gregory K. Leonard Exhibit 3 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis's Motion to	Page 6:26–27 Page 16:20–21 Page 2:20–27 Pages 3–4	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)  GRANTED (Contains trade secret and licensing
Dkt. No. 333/ (332-4) Dkt. No. 333-4/	Plaintiff's Opposition to Novartis's Motion to Strike the Second Supplemental Report of Dr. Gregory K. Leonard Exhibit 3 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis's Motion to Strike the Second	Page 6:26–27 Page 16:20–21 Page 2:20–27 Pages 3–4	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)  GRANTED (Contains trade secret and licensing negotiation terms.
Dkt. No. 333/ (332-4) Dkt. No. 333-4/	Plaintiff's Opposition to Novartis's Motion to Strike the Second Supplemental Report of Dr. Gregory K. Leonard Exhibit 3 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis's Motion to Strike the Second Supplemental Report of	Page 6:26–27 Page 16:20–21 Page 2:20–27 Pages 3–4	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)  GRANTED (Contains trade secret and licensing negotiation terms.
Dkt. No. 333/ (332-4)  Dkt. No. 333-4/ (332-6)	Plaintiff's Opposition to Novartis's Motion to Strike the Second Supplemental Report of Dr. Gregory K. Leonard Exhibit 3 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis's Motion to Strike the Second Supplemental Report of Dr. Gregory K. Leonard	Page 6:26–27 Page 16:20–21  Page 2:20–27 Pages 3–4 Page 5:8–9	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)  GRANTED (Contains trade secret and licensing negotiation terms. See Dkt. No. 332.)
Dkt. No. 333/ (332-4)  Dkt. No. 333-4/ (332-6)  Dkt. No. 333-5/	Plaintiff's Opposition to Novartis's Motion to Strike the Second Supplemental Report of Dr. Gregory K. Leonard Exhibit 3 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis's Motion to Strike the Second Supplemental Report of Dr. Gregory K. Leonard Exhibit 4 to the	Page 6:26–27 Page 16:20–21 Page 2:20–27 Pages 3–4	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)  GRANTED (Contains trade secret and licensing negotiation terms. See Dkt. No. 332.)  GRANTED
Dkt. No. 333/ (332-4)  Dkt. No. 333-4/ (332-6)	Plaintiff's Opposition to Novartis's Motion to Strike the Second Supplemental Report of Dr. Gregory K. Leonard Exhibit 3 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis's Motion to Strike the Second Supplemental Report of Dr. Gregory K. Leonard Exhibit 4 to the Declaration of Laura E.	Page 6:26–27 Page 16:20–21  Page 2:20–27 Pages 3–4 Page 5:8–9	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)  GRANTED (Contains trade secret and licensing negotiation terms. See Dkt. No. 332.)  GRANTED (Contains trade secret
Dkt. No. 333/ (332-4)  Dkt. No. 333-4/ (332-6)  Dkt. No. 333-5/	Plaintiff's Opposition to Novartis's Motion to Strike the Second Supplemental Report of Dr. Gregory K. Leonard Exhibit 3 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis's Motion to Strike the Second Supplemental Report of Dr. Gregory K. Leonard Exhibit 4 to the Declaration of Laura E. Miller in Support of	Page 6:26–27 Page 16:20–21  Page 2:20–27 Pages 3–4 Page 5:8–9	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)  GRANTED (Contains trade secret and licensing negotiation terms. See Dkt. No. 332.)  GRANTED (Contains trade secret and licensing
Dkt. No. 333/ (332-4)  Dkt. No. 333-4/ (332-6)  Dkt. No. 333-5/	Plaintiff's Opposition to Novartis's Motion to Strike the Second Supplemental Report of Dr. Gregory K. Leonard Exhibit 3 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis's Motion to Strike the Second Supplemental Report of Dr. Gregory K. Leonard Exhibit 4 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to	Page 6:26–27 Page 16:20–21  Page 2:20–27 Pages 3–4 Page 5:8–9	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)  GRANTED (Contains trade secret and licensing negotiation terms. See Dkt. No. 332.)  GRANTED (Contains trade secret and licensing negotiation terms.
Dkt. No. 333/ (332-4)  Dkt. No. 333-4/ (332-6)  Dkt. No. 333-5/	Plaintiff's Opposition to Novartis's Motion to Strike the Second Supplemental Report of Dr. Gregory K. Leonard Exhibit 3 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis's Motion to Strike the Second Supplemental Report of Dr. Gregory K. Leonard Exhibit 4 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis's Motion to	Page 6:26–27 Page 16:20–21  Page 2:20–27 Pages 3–4 Page 5:8–9	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)  GRANTED (Contains trade secret and licensing negotiation terms. See Dkt. No. 332.)  GRANTED (Contains trade secret and licensing
Dkt. No. 333/ (332-4)  Dkt. No. 333-4/ (332-6)  Dkt. No. 333-5/	Plaintiff's Opposition to Novartis's Motion to Strike the Second Supplemental Report of Dr. Gregory K. Leonard Exhibit 3 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis's Motion to Strike the Second Supplemental Report of Dr. Gregory K. Leonard Exhibit 4 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis's Motion to Strike the Second	Page 6:26–27 Page 16:20–21  Page 2:20–27 Pages 3–4 Page 5:8–9	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)  GRANTED (Contains trade secret and licensing negotiation terms. See Dkt. No. 332.)  GRANTED (Contains trade secret and licensing negotiation terms.
Dkt. No. 333/ (332-4)  Dkt. No. 333-4/ (332-6)  Dkt. No. 333-5/	Plaintiff's Opposition to Novartis's Motion to Strike the Second Supplemental Report of Dr. Gregory K. Leonard Exhibit 3 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis's Motion to Strike the Second Supplemental Report of Dr. Gregory K. Leonard Exhibit 4 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis's Motion to Strike the Second Supplemental Report of	Page 6:26–27 Page 16:20–21  Page 2:20–27 Pages 3–4 Page 5:8–9	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)  GRANTED (Contains trade secret and licensing negotiation terms. See Dkt. No. 332.)  GRANTED (Contains trade secret and licensing negotiation terms.
Dkt. No. 333-4/ (332-4)  Dkt. No. 333-4/ (332-6)  Dkt. No. 333-5/ (332-8)	Plaintiff's Opposition to Novartis's Motion to Strike the Second Supplemental Report of Dr. Gregory K. Leonard Exhibit 3 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis's Motion to Strike the Second Supplemental Report of Dr. Gregory K. Leonard Exhibit 4 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis's Motion to Strike the Second Supplemental Report of Plaintiff's Opposition to Novartis's Motion to Strike the Second Supplemental Report of Dr. Gregory K. Leonard	Page 6:26–27 Page 16:20–21  Page 2:20–27 Pages 3–4 Page 5:8–9  Page 14:8–10	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)  GRANTED (Contains trade secret and licensing negotiation terms. See Dkt. No. 332.)  GRANTED (Contains trade secret and licensing negotiation terms. See Dkt. No. 332.)
Dkt. No. 333-4/ (332-4)  Dkt. No. 333-4/ (332-6)  Dkt. No. 333-5/ (332-8)	Plaintiff's Opposition to Novartis's Motion to Strike the Second Supplemental Report of Dr. Gregory K. Leonard Exhibit 3 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis's Motion to Strike the Second Supplemental Report of Dr. Gregory K. Leonard Exhibit 4 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis's Motion to Strike the Second Supplemental Report of Plaintiff's Opposition to Novartis's Motion to Strike the Second Supplemental Report of Dr. Gregory K. Leonard Exhibit 5 to the	Page 6:26–27 Page 16:20–21  Page 2:20–27 Pages 3–4 Page 5:8–9  Page 14:8–10	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)  GRANTED (Contains trade secret and licensing negotiation terms. See Dkt. No. 332.)  GRANTED (Contains trade secret and licensing negotiation terms. See Dkt. No. 332.)
Dkt. No. 333-4/ (332-4)  Dkt. No. 333-4/ (332-6)  Dkt. No. 333-5/ (332-8)	Plaintiff's Opposition to Novartis's Motion to Strike the Second Supplemental Report of Dr. Gregory K. Leonard Exhibit 3 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis's Motion to Strike the Second Supplemental Report of Dr. Gregory K. Leonard Exhibit 4 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis's Motion to Strike the Second Supplemental Report of Plaintiff's Opposition to Novartis's Motion to Strike the Second Supplemental Report of Dr. Gregory K. Leonard	Page 6:26–27 Page 16:20–21  Page 2:20–27 Pages 3–4 Page 5:8–9  Page 14:8–10	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)  GRANTED (Contains trade secret and licensing negotiation terms. See Dkt. No. 332.)  GRANTED (Contains trade secret and licensing negotiation terms. See Dkt. No. 332.)

	Plaintiff's Opposition to Novartis's Motion to Strike the Second Supplemental Report of Dr. Gregory K. Leonard	n.72 Pages 34–36, ¶¶ 68–70, n.93, 95 Pages 37–38, ¶¶ 72–73, n.102, 104	contains proprietary pharmaceutical research and development information:  • Page 25, ¶ 53, n.63–64  • Pages 27–28, ¶ 57, n.72  See Dkt. No. 334.)
Dkt. No. 333-6/ (332-10)	Exhibit 5 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis's Motion to Strike the Second Supplemental Report of Dr. Gregory K. Leonard	Page 41, ¶ 76, n.112 Page 42, n.117–118 Page 58, ¶¶ 102, 104 Page 61–62, ¶¶ 107–110, n.185 Page 65–66, ¶¶ 113–114, n.194 Page 85, ¶ 153 Exhibit 3 (pages 1 and 2)	GRANTED (Contains trade secret and licensing negotiation terms. See Dkt. No. 332.)
Dkt. No. 333-7/ (332-12)	Exhibit 6 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis's Motion to Strike the Second Supplemental Report of Dr. Gregory K. Leonard	Entire document	<b>DENIED</b> (No supporting declaration filed. <i>See</i> Civ. L.R. 79-5(e)(1).)
J	Dkt. No. 363 – GRANTED I	N PART and DENIED IN I	PART
Dkt. No. 364/ (363-4)	Plaintiff's Offer of Proof Re: Novartis's Motion in Limine No. 2	Page 1:14–15, 20–23 Page 8:13–17 Page 9:1–2	<b>DENIED</b> (No supporting declaration filed. <i>See</i> Civ. L.R. 79-5(e)(1).)
Dkt. No. 364-2/ (363-6)	Exhibit 1 to the Declaration of Laura E. Miller in Support of Plaintiff's Offer of Proof Re: Novartis's Motion in Limine No. 2	Entire document	<b>DENIED</b> (No supporting declaration filed. <i>See</i> Civ. L.R. 79-5(e)(1).)
Dkt. No. 364-3/ (363-8)	Exhibit 2 to the Declaration of Laura E. Miller in Support of Plaintiff's Offer of Proof Re: Novartis's Motion in Limine No. 2	Entire document	<b>DENIED</b> (No supporting declaration filed. <i>See</i> Civ. L.R. 79-5(e)(1).)
Dkt. No. 364-5/ (363-10)	Exhibit 4 to the Declaration of Laura E. Miller in Support of Plaintiff's Offer of Proof	Entire document	GRANTED (Contains proprietary manufacturing information. <i>See</i> Dkt.

	Re: Novartis's Motion in Limine No. 2		No. 370.)
Dkt. No. 364-7/ (363-12)	Exhibit 6 to the Declaration of Laura E. Miller in Support of Plaintiff's Offer of Proof Re: Novartis's Motion in Limine No. 2	Entire document	<b>DENIED</b> (No supporting declaration filed. <i>See</i> Civ. L.R. 79-5(e)(1).)
Dkt. No. 364-10/ (363-14)	Exhibit 9 to the Declaration of Laura E. Miller in Support of Plaintiff's Offer of Proof Re: Novartis's Motion in Limine No. 2	Entire document	DENIED (No supporting declaration filed. <i>See</i> Civ. L.R. 79-5(e)(1).)
	Dkt. No. 366 – GRANTED		
Dkt. No. 367/ (366-5)	Plaintiff's Offer of Proof Re: Novartis's Motion in Limine No. 3	Page 16:10	GRANTED (Contains confidential sales information.  See Dkt. No. 366.)
Dkt. No. 367/ (366-5)	Plaintiff's Offer of Proof Re: Novartis's Motion in Limine No. 3	Page 6:3–11 Page 11:7–28 Page 12:1–18 Page 13:1–14 Page 14:6–18 Page 16:3, 21–22 Page 19:18–19, 27 Page 21:13–20	GRANTED IN PART (The following contains proprietary pharmaceutical research and development information:  • Page 11:7–28  • Page 12:1–18  • Page 13:1–14 See Dkt. No. 371.)
Dkt. No. 367-2/ (366-7)	Exhibit 1 to the Declaration of Laura E. Miller in Support of Plaintiff's Offer of Proof Re: Novartis's Motion in Limine No. 3	Entire document	<b>DENIED</b> (No supporting declaration filed. <i>See</i> Civ. L.R. 79-5(e)(1).)
Dkt. No. 367-3/ (366-9)	Exhibit 2 to the Declaration of Laura E. Miller in Support of Plaintiff's Offer of Proof Re: Novartis's Motion in Limine No. 3	Entire document	<b>DENIED</b> (No supporting declaration filed. <i>See</i> Civ. L.R. 79-5(e)(1).)
Dkt. No. 367-4/ (366-11)	Exhibit 3 to the Declaration of Laura E. Miller in Support of Plaintiff's Offer of Proof	Entire document	DENIED (No supporting declaration filed. <i>See</i> Civ. L.R. 79-5(e)(1).)

ourt	ornia
Inited States District Court	District of Californ
States L	
United	Northern

	Re: Novartis's Motion in		
	Limine No. 3		
Dkt. No. 367-5/	Exhibit 4 to the	Entire document	DENIED
(366-13)	Declaration of Laura E.		(No supporting
	Miller in Support of		declaration filed. See
	Plaintiff's Offer of Proof		Civ. L.R. 79-5(e)(1).)
	Re: Novartis's Motion in		
	Limine No. 3		
	Dkt. No. 368 – GRANTED	IN PART and DENIED IN	PART
Dkt. No. 369/	Plaintiff's Offer of Proof	Page 1:9–10	GRANTED IN
(368-4)	Re: Novartis's Motion in	Page 2:6–9	PART
	Limine No. 4	Page 3:16–20, 22–25	(The following
		Page 4:2–7, 11–12, 27–28	contains proprietary
		Page 5:1, 7–9, 12–16, 17–	pharmaceutical
		27	research and
		Page 6:3–6, 12–14, 16–28	development
		Page 7:1, 4–24, 26–28	information:
		Page 8:1–5, 13–16	• Page 1:9–10
		Page 9:4, 11–16, 18–28	• Page 2:6–9
		Page 10:1, 9–13	• Page 3:16–20,
		Page 11:1–4, 6–16	22–25
		Page 12:15–24	• Page 4:2–7, 11–
		Page 13:1, 4–6, 8–14, 17–	12, 27–28
		20, 23–24, 28	• Page 5:1, 7–9,
		Page 14:1–5	12–27
			• Page 6:4–7, 13– 15, 17–28
			• Page 7:1–2, 5– 25, 27–28
			• Page 8:1–6, 15–17;
			• Page 9:20–25, 27–28
			• Page 10:1–10,
			18–22
			• Page 12:26–28
			• Page 13:1–8, 11-
			• Page 14:2–3, 11-
			• Page 15:6, 14, 19
			See Dkt. No. 372.)
Dkt. No. 369-2/	Exhibit 1 to the	Entire document	DENIED
(368-6)	Declaration of Laura E.	Zittiro document	(No supporting
(200 0)	Miller in Support of		declaration filed. See
	Plaintiff's Offer of Proof		Civ. L.R. 79-5(e)(1).)

United States District Court	forthern District of California
States	Distr
United	Northern

	1	1		
	Re: Novartis's Motion in			
	Limine No. 4			
Dkt. No. 369-3/	Exhibit 2 to the	Entire document	DENIED	
(368-8)	Declaration of Laura E.		(No supporting	
Miller in Support of Plaintiff's Offer of Pro	Miller in Support of		declaration filed. See	
	Plaintiff's Offer of Proof		Civ. L.R. 79-5(e)(1).	
	Re: Novartis's Motion in			
	Limine No. 4			
Dkt. No. 374 – GRANTED				
Dkt. No. 375/	Offer of Proof Relating to	Page 10:3–27	GRANTED	
(374-4)	Plaintiff's Motion in	Page 11:1–21	(Contains proprietary	
Limine No. 1	Limine No. 1	Page 12:19–21	pharmaceutical	
		Page 13:3–18, 21–27	research and	
		Page 14:1–6, 8–9, 11–20,	development	
		22–27	information. See Dkt	
		Page 15:1, 3–4, 6–8	No. 377.)	
		Page 21:22–23		
		Page 22:1–12, 14–26		
		Page 23:3–4, 7, 9, 21–22,		
		24–26		
		Page 24:3, 5, 10, 19–22,		
		24–26		
		Page 25:1, 15–25		
	Page 26:2–6, 8–25			
	Page 27:1–4, 6–22, 26–28			
	Page 35:11–27			
	Page 36:1–26			
	Page 37:1–13			
	Page 50:23			
		Page 51:1–6, 18–20		

# III. CONCLUSION

The Court **GRANTS IN PART** and **DENIES IN PART** the parties' administrative motions to file under seal. Pursuant to Civil Local Rule 79-5(f)(1), documents filed under seal as to which the administrative motions are granted will remain under seal. The Court **DIRECTS** the parties to file public versions of all documents for which the proposed sealing has been denied, as indicated in the chart above, within seven days from the date of this order.

## IT IS SO ORDERED.

Dated: 3/13/2020

HAYWOOD S. GILLIAM, JR. United States District Judge